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ABSTRACT 
 Ebola virus (EBOV) causes severe disease in humans characterized by high case 
fatality rates and significant immune dysfunction. A hallmark of EBOV infection is the 
formation of viral inclusions in the cytoplasm of infected cells. These inclusions contain 
the EBOV nucleocapsids and are sites of viral replication and nucleocapsid maturation. 
Although there is growing evidence that viral inclusions create a protected environment 
that fosters EBOV gene expression and genome replication, little is known about their 
role in the host response to infection. The cellular stress response is an antiviral strategy 
that leads to stress granule (SG) formation and translational arrest mediated by the 
phosphorylation of the alpha subunit of eukaryotic translation initiation factor 2 (eIF2α). 
Related to this response is the post-transcriptional regulation of RNA mediated by 
stability elements called AU-rich elements (AREs) and their associated binding proteins 
(ARE-BPs), many of which are found in SGs. Because these processes have antiviral 
implications, many viruses have evolved strategies to interfere with SG formation, or 
  viii 
appropriate ARE-BPs to benefit viral replication. However, it is unknown if EBOV 
interacts with these cellular systems. Here, we show that SG proteins were sequestered 
within EBOV inclusions where they formed distinct granules that colocalized with viral 
RNA. The inclusion-bound aggregates were not canonical SGs, and did not lead to 
translational arrest in infected cells. EBOV did not induce cytoplasmic SGs at any time 
post infection, but was unable to overcome SG formation induced by additional stressors. 
Despite the sequestration of SG proteins, canonical SGs did not form within inclusions.  
At high levels of expression, viral protein 35 (VP35), the viral polymerase co-factor that 
also mediates various immune evasion functions, disrupted SGs formation independently 
of eIF2α phosphorylation. Finally, we found that the cellular ARE-BP tristetraprolin 
(TTP) specifically targeted the 3’untranslated region (UTR) of the viral nucleoprotein 
(NP) mRNA and promoted its degradation. Interestingly, TTP was not found within viral 
inclusions, leading us to speculate that inclusions might serve to prevent viral RNA from 
encountering TTP. These results indicate that EBOV interacts with the cellular stress 
response and associated RNA regulatory proteins in ways that promote viral replication. 
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CHAPTER ONE: INTRODUCTION  
 
Ebolaviruses 
History and Epidemiology 
The first documented cases of Ebola virus disease (EVD) occurred in 1976 from 
two simultaneous outbreaks of a hemorrhagic fever described in southern Sudan and 
northern Zaire, or what is now the Democratic Republic of the Congo (DRC) (Bowen et 
al., 1977; Kuhn, 2008). The outbreak in Sudan reported 284 cases with 151 deaths 
(Team, 1978), while the outbreak in Zaire reported 318 cases and 280 deaths 
(Commission, 1978). The unidentified disease presented similar illness to that of 
Marburg virus disease, which had been discovered only nine years previously (Kissling, 
Robinson, Murphy, & Whitfield, 1968; Slenczka & Klenk, 2007). It was later determined 
that these two outbreaks were caused by two distinct species of ebolavirus, named after 
the Ebola river in the DRC. According to the Centers for Disease Control and Prevention 
(CDC), since the initial outbreaks of EVD in 1976, there have been approximately 30 
additional documented human outbreaks, of varying size and severity (CDC, Outbreaks 
Chronology, 2016). The most complex and widespread outbreak began at the end of 2013 
in the West African nation of Guinea (Baize et al., 2014). Although the outbreak began in 
Guinea, there were 10 countries in total with reported cases, including four nations 
outside the continent of Africa. The greatest burden of disease fell upon only three 
countries however, Guinea, Liberia and Sierra Leone.  According to the World Health 
Organization, as of January 20th, 2016 there were 28,638 total reported cases (this 
number includes suspected, probable and confirmed cases) with 11,301 reported deaths 
  
2 
(World Health Organization, 2016). On January 14th 2016, Guinea, Liberia and Sierra 
Leone were declared Ebola free, as each country had completed the requisite 90 day 
surveillance period (World Health Organization, 2016). However, since this declaration a 
number of residual cases continue to appear, indicating that ending the outbreak will be 
difficult. The number of cases and fatalities reported for this outbreak far exceeds the 
total of all previous outbreaks combined. Even taking into considering the scale of the 
West African outbreak, the global health burden of EVD remains quite low. Prior to 
2014, there were only about 2,000 reported EVD cases with about 1500 deaths (CDC, 
Outbreaks Chronology, 2016), although under reporting due to the remote nature of most 
outbreaks is likely. The severity of disease and lack of viable treatment or vaccine 
options classify ebolaviruses as biosafety level 4 (BSL-4) pathogens and Category A 
priority pathogens by the United States Government (NIAID, 2015).  
 
Taxonomy 
Ebolaviruses belongs to the order Mononegavirales, a taxonomic grouping of 
viruses that possess a nonsegmented, negative-sense (NNS) RNA genome. This order is 
comprised of five virus families, including the family Filoviridae. Within the filovirus 
family there are three separate genera: Cuevavirus, of which no full-length viruses have 
been successfully isolated (Negredo et al., 2011), Marburgvirus, and Ebolavirus. There 
are five Ebolavirus species in total that all differ in their disease severity (Kuhn, Bào, et 
al., 2014b). Zaire ebolavirus (EBOV) is the most pathogenic, with case fatalities rates 
ranging from 40-90%, followed by Sudan ebolavirus (SUDV), Bundibugyo ebolavirus 
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(BDBV), Taї Forest ebolavirus (TAFV), and finally Reston ebolavirus (RESTV), of 
which there have been no documented human cases (Feldmann, 2014; Feldmann & 
Geisbert, 2011a). Most outbreaks of EVD are caused by either EBOV or SUDV, with the 
most recent 2014 West African outbreak caused by the Makona strain of EBOV (Baize et 
al., 2014; Kuhn, Andersen, et al., 2014a). There has been only one documented non-fatal 
case of TAFV(Le Guenno et al., 1995). BDBV is the most recently discovered 
ebolavirus, identified from an outbreak in Uganda in 2007 (Towner et al., 2008). There 
have been no human cases of RESTV, but reported epidemics in nonhuman primates and 
pigs (Barrette et al., 2009; Editorial team, 2009; T. W. Geisbert, Jahrling, Hanes, & Zack, 
1992; M. E. G. Miranda & Miranda, 2011; Rollin et al., 1999).    
 
Ecology 
 With the exception of RESTV, ebolaviruses are endemic to Africa, with outbreaks 
typically occurring in equatorial regions of the continent. Prior to the 2014 outbreak in 
West Africa, only one case of a natural EVD infection had ever been documented in 
humans outside of this central African region. This incident involved only one case of 
TAFV in Cote d’Ivoire, which the patient survived (Le Guenno, Formenty, & Boesch, 
1999). Interestingly, RESTV was the first documented natural infection of an ebolavirus 
in nonhuman primates in the Philippines, as well as the only virus in this family with 
origins outside of Africa (M. E. G. Miranda & Miranda, 2011).        
 Due to the severity of disease and high case fatality rates in both humans and 
nonhuman primates associated with many ebolaviruses, it is thought that these species do 
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not represent a suitable reservoir. Combined with the notion that a majority of emerging 
infectious diseases are zoonotic in nature (K. E. Jones et al., 2008), considerable effort 
has been made attempting to identify a host species or arthropod vector. An extensive 
sampling study of wildlife in areas near outbreaks of chimpanzee and gorilla populations 
in Gabon and the DRC suggested that fruit bats might represent a potential reservoir. This 
conclusion was based on the presence of virus specific IgG in serum collected from three 
different bat species, as well as viral nucleotide sequences detected by PCR (Leroy et al., 
2005).  However, in this study viral RNA was never isolated from any bat, making it 
difficult to conclude with certainty that they are in fact the reservoir.  Intriguingly, it was 
later discovered that the fruit bat Rousettus aegyptiacus might be the reservoir species for 
Marburg virus (Towner et al., 2007). Bats are encountered quite frequently in filovirus 
endemic areas, and represent a common food source for many people in these regions 
(Leroy et al., 2009). While it is still unclear what the precise animal reservoir(s) may be, 
evidence strongly points to fruit bats as hosts.  
 
Clinical Course of Disease 
Clinical Manifestations 
The severity of EVD is dependent upon on the species or strain and can vary 
considerably. It is important to note that outbreaks typically occur in geographically 
remote locations in populations with a high prevalence of comorbidities. This has made it 
difficult to study the clinical course of disease in humans.  However, it is generally 
thought that the course of disease occurs quite rapidly with symptoms that are often 
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severe and complex. The viral incubation period ranges from 2-21 days followed by the 
abrupt onset of non-specific symptoms including fever and malaise. These symptoms 
quickly develop into more severe and systemic symptoms including nausea, vomiting, 
anorexia, and diarrhea. Signs of hemorrhage, attributed in part by disseminated 
intravascular coagulation, are present in less than half of patients but typically present at 
the height of infection and are characterized by mucosal hemorrhage and uncontrollable 
bleeding from venipuncture sites (T. W. Geisbert, Young, et al., 2003b). A macropapular 
rash is also often a characteristic at later stages of infection. Those who succumb to fatal 
infection typically die from complications associated with hypovolemic shock, multi-
organ failure, and severe metabolic dysfunction (Bah et al., 2015; Lyon et al., 2014; T. 
W. MD et al., 2015b; Zaki & Goldsmith, 1999). Recent data collected from survivors 
during the 2014 West African outbreak indicate that convalescence is associated with a 
number of sequelae, many of which are still poorly understood.  Common among these 
include severe headaches and other neurological symptoms, joint pain, and ocular 
degeneration (“Examination of the Retina,” 2015; Mattia et al., 2015). The complications 
of what is being termed “post-Ebola syndrome” are of increasing interest to both 
researchers and clinicians alike.  
 
Transmission 
As zoonotic pathogens, ebolaviruses can spread between and among animals and 
humans. Animal to human transmission typically occurs through the hunting and 
consumption of infected animals, or the handling of animal carcasses. Successful human-
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to-human transmission also only occurs via close contact with bodily fluids of an infected 
individual. Outbreaks are often initiated by a single introduction of virus from wildlife, 
either the reservoir species or another end host species (Baize et al., 2014; Feldmann & 
Geisbert, 2011). Sites of exposure typically include mucosal surfaces or breaks in the 
skin barrier. Laboratory exposure, although rare, has also been reported, and was due to 
needlestick injury or improper handling of blood (Emond, Evans, Bowen, & Lloyd, 1977; 
“ProMED-mail post,” 2016; rpt4, 2008).  
Although not exhaustively studied, evidence indicates that EBOV can remain in 
certain areas of the body for extended periods of time, even after the apparent clearance 
of virus from the blood. These sites include the central nervous system, the eye, breast 
milk and semen (Akerlund, Prescott, & Tampellini, 2015; Heeney, 2015; Kelly, 
Richardson, & Barry, 2015). A recent study examined the persistence of EBOV in the 
semen of male survivors and found that viral RNA could be detected in seminal fluid up 
to nine months after the onset of illness (G. F. Deen et al., 2015; Mate et al., 2015). This 
finding is therefore indicative of spread through sexual contact. Other evidence 
suggestive of viral persistence or latency includes the reports from one survivor who was 
found to harbor EBOV within his eye after discharge from the hospital and in spite of 
negative blood and urine tests (Varkey et al., 2015; Yeh, Varkey, & Crozier, 2015). 
These examples of viral persistence despite disease recovery highlight the need to 




Treatments and Vaccines 
As of January 2016 there are no licensed vaccines or therapeutic options available 
for EVD.  Currently, treatment is limited to intensive supportive care, with particular 
emphasis on rehydration, nutritional support and treatment of comorbidities (J. Deen, 
Dondorp, & White, 2015b; Mehta, Lyon, & Varkey, 2015). A number of experimental 
treatments have been employed during the 2014 West African outbreak (Hoenen & 
Feldmann, 2014) including the use of convalescent serum or plasma (van Griensven, De 
Weiggheleire, et al., 2016; van Griensven, Edwards, et al., 2016), small interfering RNAs 
(siRNAs) (Kraft et al., 2015), and monoclonal antibody cocktails (Lyon et al., 2014; 
Marzi et al., 2012; Qiu et al., 2013). Many of these potential therapeutics are undergoing 
testing in clinical trials but their efficacy remains inconclusive. Similarly, testing and 
clinical trials of a number of experimental vaccines were also made a priority during the 
2014 outbreak. While a number of vaccines have been developed and tested in animal 
models of EVD (Hoenen, Groseth, & Feldmann, 2012; Marzi & Feldmann, 2014), not all 
have been approved for use in humans. A number of promising candidates have emerged 
however, and include a recombinant vesicular stomatitis virus (VSV) based vaccine 
(Agnandji et al., 2015; Huttner et al., 2015; Marzi et al., 2015) and chimpanzee 
adenovirus 3-based vaccine(M. D. T. MD et al., 2015a; Stanley et al., 2014). Phase II and 
III clinical trials of each vaccine are currently underway in West Africa (World Health 




Viral Components and Pathogenesis  
Genome and Viral Proteins 
As a member of the order Mononegavirales, EBOV possesses a non-segmented 
negative-sense RNA genome that is roughly 19 kilobases in length. The single stranded 
genome, depicted in Figure 1, encodes seven genes that produce seven structural proteins. 
At the terminal 3’ and 5’ ends of the genome are extragenic regions termed the leader and 
trailer, that contain promoters for replication and transcription (Mühlberger, 2007; 
Neumann, Watanabe, & Kawaoka, 2009). The seven structural proteins produced include 
the nucleoprotein (NP), the polymerase cofactor viral protein 35 (VP35), the matrix 
protein VP40, the glycoprotein (GP), transcriptional cofactor VP30, the minor matrix 
protein VP24, and the polymerase L. Viral replication and transcription take place in the 
cytoplasm of infected cells and are carried out by the RNA-dependent RNA polymerase 
(RDRP) L, in conjunction with VP35 and VP30.  Like other NNS viruses, the EBOV 
polymerase complex initiates transcription at a single transcription promoter at the 3’ end 
of the genome then proceeds towards the 5’end to transcribe each gene sequentially. The 
polymerase is thought to occasionally dissociate from the genome, predominantly at the 
gene borders, forcing it to reinitiate transcription back at the 3’ transcription promoter. 
This creates a gradient of transcribed viral mRNAs, with a higher abundance of 
transcripts produced from genes found closer to the transcription promoter compared to 
those more distally located (Brauburger et al., 2014; Shabman et al., 2013; Whelan, Barr, 
& Wertz, 2004). The seven resulting monocistronic mRNAs are all 5’-capped and 3’-
polyadenylated. Replication leads to the production of a positive-sense replication 
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intermediate called the antigenome. This intermediate serves as a template for genome 
replication.  Both the genome and the antigenome are encapsidated by the nucleocapsid 
complex, composed of NP, VP35, VP30 and VP24 (genome replication and transcription 
reviewed in (Messaoudi, Amarasinghe, & Basler, 2015; Mühlberger, 2007; Neumann et 




Figure 1. Schematic of the EBOV genome.   
The EBOV negative sense ssRNA genome is approximately 19 kb in length and contains 
seven genes. Each gene, represented by a green box, contains an open reading frame 
(ORF) that is flanked by long untranslated regions (UTRs). At each end of the genome 
are short extragenic regions, the leader and the trailer. The leader and the trailer 
compliment, which is found on the antigenome, contain cis-acting elements required for 






EBOV entry into the body typically occurs though a mucosal surface or a breach 
in the skin barrier. Primary targets of infection include monocytes, macrophages and 
dendritic cells (T. W. Geisbert, Hensley, et al., 2003a; Ryabchikova et al., 1996). These 
cells presumably contribute to the widespread dissemination of the virus from initial sites 
of infection to nearly every tissue in the body, particularly the liver and spleen, via the 
blood and lymphatic system. EBOV infection leads to significant immune dysfunction, 
starting with the release of inflammatory cytokines and chemokines (Baize et al., 2002; 
Mohamadzadeh, Chen, Olinger, Pratt, & Schmaljohn, 2006). Fatal infection is 
characterized by an uncontrolled inflammatory response that contributes to a state of 
sepsis-like shock (Baize et al., 2002; 1999; Feldmann & Geisbert, 2011a).  Infection 
studies using monocyte-derived dendritic cells showed that EBOV infection prevents 
their maturation and subsequent interaction and antigen-presenting function to T cells 
(Bosio et al., 2003; Lubaki et al., 2013; Mahanty et al., 2003). Further contributing to an 
impaired immune response is the development of lymphopenia targeting CD4+ and CD8+ 
T cells, as well as natural killer cells (Baize et al., 1999; Bradfute et al., 2010; Gupta, 
Spiropoulou, & Rollin, 2007; Reed, Hensley, Geisbert, Jahrling, & Geisbert, 2004). 
Additionally, EBOV encodes several proteins that are involved in the inhibition and 
antagonism of the innate immune response (reviewed in (Basler, 2015)).  This is 
primarily mediated by VP35, which serves many immune evasion functions. These 
functions include but are not limited to blocking type I interferon (IFN) production by 
preventing the phosphorylation of interferon regulatory factor 3 (IRF-3)(Basler et al., 
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2003), impairing retinoic acid-inducible gene 1 (RIG-I) signaling (Cárdenas et al., 2006; 
Luthra et al., 2013), and protein kinase R (PKR) antagonism (Feng, Cerveny, Yan, & He, 
2007a; Schümann, Gantke, & Mühlberger, 2009).  Similarly, VP24 has been shown to 
block IFN signaling by preventing the nuclear translocation of signal transducers and 
activators of transcription 1 (STAT1) (Mateo, Reid, Leung, Basler, & Volchkov, 2010; 
Reid et al., 2006; W. Xu et al., 2014). Overall, significant immune evasion and 
dysfunction combined with widespread viral dissemination and cellular pantropism 
contribute to the relatively uninhibited viral amplification and high levels of viremia 
observed during EBOV infection.   
 
Viral Nucleocapsid Complexes and Inclusions 
 Concurrent with viral RNA synthesis is the encapsidation and packaging of 
EBOV genomic and antigenomic RNAs by NP. Mediated through the interaction with the 
other nucleocapsid proteins (VP35, L, VP30 and VP24), either directly or via linker 
proteins, NP serves as a nucleating factor for the formation of ribonucleoprotein 
complexes (RNPs) or nucleocapsids (NCs).  Within the cytoplasm these NCs aggregate 
into highly ordered structures called viral inclusions, which are the sites of viral 
replication and nucleocapsid maturation (Hoenen et al., 2012b; Nanbo, Watanabe, 
Halfmann, & Kawaoka, 2013a; Schudt et al., 2015). The first morphological sign of 
EBOV inclusion formation, as visualized by electron microscopy (EM), is the presence of 
viral granular material, composed of viral proteins and RNA, at about 9 hours post 
infection (Ryabchikova & Price, 2004). This appearance of granular material is followed 
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by the development of highly organized inclusions, consisting of tubular structures 
roughly 50 nm in diameter (Noda, Aoyama, Sagara, Kida, & Kawaoka, 2005; Noda et al., 
2006). NP, in the absence of the other nucleocapsid components, oligomerizes into loose 
helices that serve as drivers of NC-like structure formation in the cytoplasm (Nanbo, 
Watanabe, Halfmann, & Kawaoka, 2013b; Noda et al., 2006). Co-overexpression of NP, 
VP24 and VP35 yields inclusions that are morphologically indistinguishable from those 
observed during EBOV infection (Huang, Xu, Sun, & Nabel, 2002; Noda et al., 2005; 
2006).    
 
EBOV Proteins VP35 and VP30 
During EBOV infection, the virus employs a number of immune evasion 
strategies, many of which are mediated by the multifunctional protein VP35. This protein 
is considered to be the filovirus analog to the phosphoproteins (P) of other NNS viruses, 
which are part of the ribonucleoprotein complexes required for viral replication 
(Conzelmann, 1998; Rahmeh et al., 2012; Whelan et al., 2004). In addition to its role as a 
nucleocapsid component and polymerase cofactor, VP35 counteracts type I interferon 
induction (Bale et al., 2013; Basler et al., 2003; 2000; Cárdenas et al., 2006; Hartman, 
Towner, & Nichol, 2004; D. W. Leung, Prins, Basler, & Amarasinghe, 2010; Prins, 
Cárdenas, & Basler, 2009), blocks RNA interference pathways (Fabozzi, Nabel, Dolan, 
& Sullivan, 2011; Haasnoot et al., 2007; Zhu et al., 2012) and antagonizes the activation 
of the dsRNA sensor PKR (Feng, Cerveny, Yan, & He, 2007b; Schümann et al., 2009). 
VP35’s IFN inhibition function can be traced to a C-terminal domain, the interferon 
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inhibitory domain (IID), that contains a stretch of basic residues and binds dsRNA 
(Kimberlin et al., 2010; D. W. Leung et al., 2009). A single mutation to either arginine 
309 or lysine 312 in the has been shown to abrogate dsRNA binding (Cárdenas et al., 
2006; Hartman et al., 2004; D. W. Leung et al., 2009). The IID shares sequence similarity 
to the amino-terminal dsRNA binding domain of the influenza A virus (IAV) NS1 
protein, a well characterized IFN antagonist (Hartman et al., 2004). NS1 is also able to 
antagonize PKR and disrupt the type I IFN response via dsRNA binding and IRF-3 
inhibition (García-Sastre, 2001; Krug, Yuan, Noah, & Latham, 2003; Shoudong Li, Min, 
Krug, & Sen, 2006), and has been shown to prevent stress granule (SG) formation during 
IAV infection (Khaperskyy et al., 2014; Khaperskyy, Hatchette, & McCormick, 2012; 
Mok et al., 2012). These two viral proteins are thus functionally very similar.  
In addition to its ability to bind dsRNA, VP35 also has a number of protein 
binding partners. As part of nucleocapsid complexes and viral inclusions, VP35 interacts 
with both L (Prins et al., 2010; Trunschke et al., 2013) and NP (Noda, Hagiwara, Sagara, 
& Kawaoka, 2010; Noda, Kolesnikova, Becker, & Kawaoka, 2011) directly, and is 
thought to act as a bridge between the two (Becker, Rinne, Hofsäss, Klenk, & 
Mühlberger, 1998; Boehmann, Enterlein, Randolf, & Mühlberger, 2005). Co-expression 
of VP35 and NP in cells leads to the formation of inclusion bodies that are similar to 
those found in infected cells. With the addition of VP24 these inclusions are structurally 
identical to those found in infected cells (Huang et al., 2002; Noda et al., 2006). VP35 
binds to NP via two unique binding sites, which independently localize VP35 to viral 
inclusions, or maintain NP in a monomeric, RNA free state (Kirchdoerfer, Abelson, Li, 
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Wood, & Saphire, 2015; D. W. Leung et al., 2015). When expressed in excess of NP, 
VP35 is able to disrupt the structure of viral inclusions, indicating that the NP to VP35 
ratio is important for efficient viral replication (Noda et al., 2010; 2011). A number of 
cellular proteins have also been shown to bind VP35, including protein activator of the 
interferon-induced protein kinase (PACT), a key component of RNA interference and 
IFN pathways,(Fabozzi et al., 2011; Luthra et al., 2013; Zhu et al., 2012), DRP76, a 
regulator of PKR activation (Shabman et al., 2011) and the light chain of the molecular 
motor dynein (Luthra, Jordan, Leung, Amarasinghe, & Basler, 2015). It is presumably 
through these diverse RNA and protein interactions that VP35 mediates its functions 
during EBOV infection.  
Similar to VP35, VP30 is a component of EBOV nucleocapsid complexes and can 
be found in viral inclusions (Hoenen et al., 2012b; Nanbo, Watanabe, Halfmann, & 
Kawaoka, 2013b). However, while VP35 is required for viral genome replication, VP30 
is dispensable for this function, and is instead a critical transcription activator and 
reinitiation factor (Martinez et al., 2008; Mühlberger, Weik, Volchkov, Klenk, & Becker, 
1999). The function of VP30 during viral transcription has not been precisely defined, 
however it has been shown that if the RNA hairpin loop secondary structure found in the 
transcription start signal of the first viral gene, NP, is destroyed, transcription no longer 
requires VP30 (Weik, Modrof, Klenk, Becker, & Mühlberger, 2002).  It is thus thought 
that VP30 plays a role at early stages of viral transcription.  
VP30 is able to bind the other nucleocapsid components NP (Modrof, 
Mühlberger, Klenk, & Becker, 2002), VP35 (Biedenkopf, Hartlieb, Hoenen, & Becker, 
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2013), and L (Groseth et al., 2009). It also forms homo-oligomers, which are required for 
viral transcription, but are dispensable for its interaction with EBOV nucleocapsids 
(Hartlieb, Modrof, Mühlberger, Klenk, & Becker, 2003). The phosphorylation of VP30 at 
two N-terminal serine clusters has been shown to also regulate its various functions 
(Modrof et al., 2002). Phosphorylation of VP30 led to decreased transcription and 
enhanced viral replication, while the unphosphorylated form of VP30 promoted viral 
transcription and repressed viral replication, suggesting that VP30 influences the balance 
between replication and transcription, depending on its phosphorylation state 
(Biedenkopf et al., 2013; Ilinykh et al., 2014; Martinez et al., 2011; Modrof et al., 2002). 
The cellular phosphatases protein phosphatase 1 (PP1) and 2A (PP2A) have been shown 
to dephosphorylate VP30, and are thus able to influence its activity during viral infection 
(Ilinykh et al., 2014; Modrof et al., 2002). Furthermore, it was shown that targeting PP1 
with a small molecular inhibitor lead to an increase in VP30 phosphorylation, which 
inhibited viral transcription and suppressed viral replication in Vero-E6 cells (Ilinykh et 
al., 2014). These data suggest that VP30 is a promising target for antivirals.      
Unlike VP35, VP30 binds to ssRNA, a function that can be mapped to a stretch of 
basic amino acids located in the N-terminus, and requires Zn2+ ions (John et al., 2007). 
Also located in the N-terminus is a Cys3His (CCCH) zinc finger domain, which is 
required for VP30’s transcriptional activity, but has no effect on its interaction with NP 
and viral inclusions (John et al., 2007; Modrof, Becker, & Mühlberger, 2003). The 
respiratory syncytial virus (RSV) homolog of VP30, M2-1, also contains this unique 
CCCH zinc finger motif, which was shown to be required for M2-1’s function in RSV 
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transcription (Hardy & Wertz, 2000; Tang, Nguyen, Cheng, & Jin, 2001). Interestingly, 
the CCCH motif is found almost exclusively in cellular proteins that mediate the post-
transcriptional regulation of mRNA stability, such as tristetraprolin (TTP) and butyrate 
response factor 1 (BFR1) (Lai, Carballo, Thorn, Kennington, & Blackshear, 2000; Lai, 
Kennington, & Blackshear, 2002).  Another cellular protein containing four CCCH 
motifs is zinc-finger antiviral protein (ZAP) which has been shown to target viral 
mRNAs and promote their degradation, including the EBOV and MARV L mRNA (Gao, 
Guo, & Goff, 2002; Jeong, Kim, & Jang, 2010; Müller et al., 2007; Wang, Lv, & Gao, 
2010). The presence of this unique CCCH motif in VP30 thus suggests that it might be 
involved in regulating mRNA stability. 
 
The Cellular Stress Response and mRNA Regulation 
 
The regulation of mRNA stability and translation represents an important post-
transcriptional checkpoint leading to appropriate yet dynamic protein expression and is 
particularly important for quickly fine-tuning cellular responses to changes in the 
environment or returning cells to a state of homeostasis. The availability and abundance 
of mRNA transcripts to the host translation machinery are two important factors that 
influence the outcome of a cellular response to changes in the environment. These can be 
controlled by the integrated stress response and the regulation of mRNA stability, 




The Integrated Stress Response 
Exogenous environmental stress such as heat, nutrient deprivation, ultraviolet 
radiation and viral infection can trigger the cellular stress response, which acts as a form 
of mRNA triage to prioritize the translation of those mRNAs that are essential for cell 
survival. Four cytoplasmic kinases sense these various forms of stress and initiate the 
signaling cascade that eventually leads to a state of translational arrest (Anderson & 
Kedersha, 2008; 2009a). These kinases include PKR, heme-regulated inhibitor kinase 
(HRI), PKR-like endoplasmic reticulum kinase (PERK), and general control 
nonderepressible 2 (GCN2), which sense dsRNA, oxidative stress, ER stress, and amino 
acid deprivation, respectively. Upon activation, these kinases phosphorylate the α-subunit 
of eukaryotic translation initiation factor 2 (eIF2α), thereby preventing the assembly of 
the ternary pre-initiation complex, which is required to bring tRNAmet to the 40S 
ribosomal subunit. This leads to the accumulation of stalled translation initiation 
complexes on mRNAs and triggers the aggregation of other RNA binding proteins 
(Anderson & Kedersha, 2009b; Kedersha & Anderson, 2009). These complex and highly 
dynamic aggregates of mRNA and protein are referred to as stress granules (SGs). SGs 
are non-membranous granules that form exclusively in the cytoplasm and are typically 1-
2 µm in diameter (Souquere et al., 2009). A schematic of eIF2α-induced SG formation is 
depicted in Figure 2.  
The protein composition of SGs can vary depending on the type of stress present, 
but many SG proteins, such as Ras GTPase-activating protein-binding protein 1 (G3BP) 
and T-cell restricted intracellular antigen 1 (TIA-1) are consistent across all SG types and 
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are therefore considered canonical SG components. These proteins are also critical 
drivers of the nucleation of SGs, and can even induce SG formation at sufficiently high 
levels of cytoplasmic protein expression in the absence of stress (Anderson & Kedersha, 
2009a; Buchan & Parker, 2009; Thomas, Loschi, Desbats, & Boccaccio, 2011). In 
addition to mRNA and translation factors, SGs include other protein components such as 
scaffold proteins, RNA helicases, RNA binding proteins involved in mRNA stability, and 
components of other signaling pathways (Kedersha, Ivanov, & Anderson, 2013).  
SGs can persist for many hours, but they are highly dynamic structures that 
depend on microtubule networks for assembly and disassembly (Bartoli, Bishop, & 
Saunders, 2011; Loschi, Leishman, Berardone, & Boccaccio, 2009). Live cell imaging 
studies have shown that SG components, including TIA-1 and poly-A binding protein 
(PABP) can shuttle into and out of SGs continuously (Kedersha et al., 2000; 2005), 
however it is unknown if all SG components behave as such.  Further evidence 
suggesting that SGs are highly dynamic is the observation that mRNA, another canonical 
component of SGs, can shuttle between polysomes, SGs, and processing bodies (P-
bodies), which are another type of cellular RNA granule (Anderson & Kedersha, 2006; 
Kedersha et al., 2005). While SGs focus on diverting translational energy towards the 
expression of proteins involved in cell survival, P-bodies are enriched in mRNA decay 
machinery suggesting they are important for the degradation and processing of mRNAs 
(Anderson & Kedersha, 2009a). Unlike SGs, P-bodies are constitutively present in cells 
but can increase in size and number under conditions of stress (Eulalio, Behm-Ansmant, 
& Izaurralde, 2007; Teixeira, Sheth, Valencia-Sanchez, Brengues, & Parker, 2005). 
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Because of their dynamic nature and complex compositions, P-bodies and SGs are 
difficult to study and methods for their characterization are limited to mainly microscopy 
and other forms of cellular imaging (Brielle, Gura, & Kaganovich, 2015; Panas, 





Figure 2. Basic scheme of SG induction.  
Cellular stress is sensed by the four cytoplasmic kinases, PKR, PERK, GCN2, and HRI, 
which sense viral infection, ER stress, nutrient deprivation and oxidative stress, 
respectively. Upon activation, these kinases phosphorylate the alpha subunit of eIF2, 
which ultimately prevents the formation of complete translation initiation complexes.  
Stalled translation leads to the accumulation of a number of translation initiation factors, 
RNA binding proteins, mRNA and 40S ribosomal subunits, ultimately resulting in the 
formation of SGs and translational arrest.     
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Stress Granule Formation and Viral Infection 
The global decrease in protein translation associated with SG formation is 
unsustainable for viral replication, which requires the host translational machinery to 
synthesize viral proteins. Therefore, many viruses have evolved strategies to antagonize 
the stress response. Few viruses have been shown to co-exist with fully formed SGs over 
the entire course of infection. Hepatitis C virus (HCV) is one of the few examples of such 
viruses, and has been shown to induce eIF2α phosphorylation and SG formation during 
infection and use the associated host translational arrest to block interferon production, 
thus using the stress response to its own advantage (Garaigorta & Chisari, 2009). HCV is 
able to maintain the translation of its own polyprotein via an internal ribosome entry site 
(IRES), which is an eIF2α independent translation strategy (Garaigorta, Heim, Boyd, 
Wieland, & Chisari, 2012; Thakor & Holcik, 2012). A majority of viruses however, have 
been shown to either induce SGs early during infection, but disrupt SG formation later 
when viral protein levels are high, or to suppress SG formation during the entirety of the 
infection (Montero & Trujillo-Alonso, 2011; J. P. White & Lloyd, 2012). A number of 
viruses, including EBOV, have been shown to prevent PKR activation (Feng, Cerveny, 
Yan, & He, 2007b; Schümann et al., 2009; J. P. White & Lloyd, 2012). IAV does not 
induce SG formation at any time during infection and is able to prevent PKR activation 
via its viral protein NS1 (Khaperskyy et al., 2012). Similarly, the arenavirus Junín virus 
was shown to inhibit SG formation by impairing eIF2α phosphorylation, via an 
undetermined mechanism (Linero, Thomas, Boccaccio, & Scolaro, 2011). Other viruses 
are able to prevent SG formation through the cleavage of important SG components. 
  
23 
During poliovirus infection, SGs are induced early but are later disrupted via the cleavage 
of G3BP by the viral protease 3C (J. P. White & Lloyd, 2011; J. P. White, Cardenas, 
Marissen, & Lloyd, 2007).  Finally, other viruses have been shown to sequester or 
subvert critical SG components. The alphavirus chikungunya virus represses SG 
formation through the recruitment of G3BP by the viral protein nsp3 to cytoplasmic foci 
that resemble SGs. These aggregates are compositionally distinct from canonical SGs 
however, and were shown to enhance viral replication (Fros et al., 2012; Scholte et al., 
2015). Similarly, the flaviviruses West Nile virus and dengue virus do not induce SG 
formation during infection but show strong interaction with SG proteins TIA-1 and TIAR 
(Courtney, Scherbik, Stockman, & Brinton, 2012; B. Jain, Chaturvedi, & Jain, 2014; W 
Li et al., 2002; Xia et al., 2015). Dengue virus was also shown to induce the formation of 
G3BP1 granules in lung epithelial cells. These granules did not contain TIA-1, 
distinguishing them from canonical SGs (Xia et al., 2015). The increasing number of 
studies demonstrating an interaction between SGs and viruses highlights the significance 
of this response during viral infection. Furthermore, viruses employ a range of different 
mechanisms to prevent or exploit SGs and their components, which emphasizes the 
complex and unique interactions between them. 
 
Regulation of mRNA Stability via AU-Rich Elements 
AU-rich elements (AREs) are cis-acting elements located within the 3’-
untranslated region (3’UTR) of mRNAs. AREs are able to modulate mRNA stability and 
subsequent protein translation via their interaction with associated RNA binding proteins 
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(RBPs). The function of AREs as mechanisms of mRNA decay was first discovered in 
1986, when an AT-rich region from the 3’UTR of the granulocyte-macrophage colony 
stimulating factor (GM-CSF) gene, which would become an AU rich region in the 
transcribed mRNA, was fused to the rabbit β-globin gene. In this experiment, the 
recombinant β-globin gene, which produces a generally stable mRNA, instead resulted in 
a highly unstable mRNA that was rapidly degraded (Shaw & Kamen, 1986). It has now 
been established that many mRNAs, particularly those of cytokine and growth factors, 
possess AREs in the 3’UTRs (Beisang & Bohjanen, 2012; Kafasla, Skliris, & 
Kontoyiannis, 2014; Vlasova-St Louis & Bohjanen, 2014).   
AREs are highly variable and are therefore difficult to define precisely. They have 
been loosely classified into three main groups. However, there are many known AREs 
that do not fall into these three categories. Class I AREs contain 1-3 copies of the 
pentameric sequence AUUUA throughout the UTR and are often surrounded by areas 
that are U-rich. Class II AREs typically contain 5-8 overlapping copies of the AUUUA 
motif.  Finally, Class III AREs are comprised of predominately U-rich sequences and 
may lack the AUUUA motif altogether (C. Y. Chen & Shyu, 1995; Roretz, Marco, 
Mazroui, & Gallouzi, 2010; Vlasova-St Louis & Bohjanen, 2014; Wu & Brewer, 2012).  
The developers of an online database of ARE-containing transcripts found in different 
species (ARED Organism) introduced a second classification system. This new grouping 
contains five different categories of ARE, and distinguishes them based on the number of 
overlapping AUUUA pentamers, from one to five, respectively (Halees, El-Badrawi, & 
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Khabar, 2008). The different classification schemes are useful but are ultimately not 
sufficient to fully categorize the spectrum of observed AREs.   
 
ARE-Binding Protein Tristetraprolin (TTP)  
 AREs are recognized by various RBPs that comprise complex regulatory 
networks and promote mRNA stability or degradation (Barreau, Paillard, & Osborne, 
2005; C. Y. Chen & Shyu, 1995; Wu & Brewer, 2012). TTP is a canonical and well-
characterized ARE-BP) that contains a CCCH zinc finger motif and targets mRNAs for 
degradation (Brooks & Blackshear, 2013; Lai et al., 2000).  TTP was first functionally 
characterized in studies examining TTP knock out mice. It was found that these mice 
exhibited severe inflammation, cachexia and autoimmunity (Taylor et al., 1996). This 
paper established that TNF-α was a target of TTP, and mice deficient in TTP 
demonstrated unrestricted TNF-α expression, resulting in the immunological pathologies 
observed. It was later determined that TTP binds to ssRNA via its two tandem CCCH 
zinc finger motifs. A single mutation to any one of the Cys or His residues of the zinc 
finger domains was sufficient to ablate RNA binding (Lai et al., 2000). The list of TTP 
targets continues to expand since the initial studies examining TTP’s effect on TNF-α in 
1996 and includes many cytokine and growth factors. Interestingly, TTP has been shown 
to regulate the stability of its own mRNA, as well as various viral mRNAs (Brooks, 
Connolly, & Rigby, 2004; Maeda et al., 2006). TTP is also known to interact with a 
number of cellular proteins, particularly those involved in mRNA decay. These include 
decapping, deadenylating and exosome proteins (Brooks & Blackshear, 2013). Important 
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to its function is the phosphorylation of TTP. The p38 mitogen activated protein kinase 
(MAPK) pathway seems to be primarily responsible for controlling TTP function. Both 
MAPK-activated protein kinase 2 (MK2) and p38 can phosphorylate TTP, which 
promotes binding of the chaperone protein 14-3-3 and thereby inactivates TTP (Mahtani 
et al., 2001; Stoecklin et al., 2004; L. Sun et al., 2007).   
Because TTP is a potent regulator of mRNA stability, it is also involved in the 
cellular response to stress. TTP has been shown to localize to SGs upon energy 
deprivation but is excluded from arsenite-induced SGs (Roretz et al., 2010). This 
difference is thought to be due to the p38-MAPK mediated phosphorylation of TTP and 
subsequent binding to 14-3-3, induced during oxidative stress (Stoecklin et al., 2004). 
TTP can also be found in P-bodies, which are known to be enriched in RNA decay 
machinery (Brooks & Blackshear, 2013; L. Sun et al., 2007). The precise mechanisms 
that determine the localization of specific ARE-BPs and their associated mRNAs to SGs 
or P-bodies under conditions of stress are still poorly understood.   
Evidence also suggests that TTP, like many other ARE-BPs, can interact with 
viral RNA and thus influence the outcome of viral infection.  TTP has been shown to 
bind to human immunodeficiency virus 1 (HIV-1) genomic RNA, which is AU-rich (Graf 
et al., 2000; Maeda et al., 2006).  TTP skews the ratio of HIV RNA splicing products, 
thereby altering the expression of certain HIV proteins which leads to reduced HIV virion 
production (Maeda et al., 2006).  It remains to be determined if TTP functions as an 
antiviral protein in EBOV infection.  
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ARE-Binding Protein Human antigen R (HuR) 
 Human antigen R (HuR) is another well-studied ARE-BP that promotes mRNA 
stability and protein translation (Brennan & Steitz, 2001; Simone & Keene, 2013). HuR 
mediates a number of biological functions aside from post-transcriptional regulation of 
mRNA.  It is involved in the cellular stress response (Yamasaki & Anderson, 2008) is 
thought to be anti-apoptotic and regulates cellular differentiation (Cherry, Karschner, 
Jones, & Pekala, 2006; Hinman & Lou, 2008; Lal, Kawai, Yang, Mazan-Mamczarz, & 
Gorospe, 2005). A complete knock out is embryonic lethal in mice, highlighting its 
important contributions to cellular growth and differentiation (Antic & Keene, 1997; 
Ghosh et al., 2009; Lebedeva et al., 2011). HuR is predominately located in the nucleus 
but shuttles to the cytoplasm under conditions of stress (Brennan & Steitz, 2001). It 
shares many mRNA targets with TTP, including TNF-α, and as such, competition exists 
between them, adding another layer of regulation to their respective functions (Anderson, 
2010; Vlasova-St Louis & Bohjanen, 2014). It is thought that one contribution of HuR to 
mRNA stability is through the competitive binding with other destabilizing ARE-BPs 
(Garneau, Wilusz, & Wilusz, 2007; Lal et al., 2004; Roretz et al., 2010). HuR can be 
activated by a number of different stresses including ultraviolet radiation, heat shock, and 
oxidative stress and can be found in cytoplasmic SGs (Anderson & Kedersha, 2009a; 
Gallouzi et al., 2000; Masuda, Abdelmohsen, & Gorospe, 2009; Roretz et al., 2010). 
Similar to other ARE-BPs, HuR can be phosphorylated at various sites, which influence 
HuR’s function, and can determine its cellular localization (Brennan & Steitz, 2001; 
Simone & Keene, 2013).   
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As a promoter of mRNA stability, HuR is an attractive cellular target during viral 
infection, and has been shown to interact with a number of different viruses. The 3’UTR 
of the classic swine fever virus genome was identified as a target of HuR. However, the 
contribution of HuR to viral replication remains undetermined (Nadar et al., 2011). 
Similarly, HuR was shown to bind to the 3’UTR of Sindbis virus mRNA during 
infection, thus promoting productive infection (Sokoloski et al., 2010). RSV, which 
forms inclusion bodies similar to those observed during EBOV infection, was also shown 
to sequester HuR within these inclusions. However, the precise function of HuR during 
RSV infection remains unclear (Lindquist, Lifland, Utley, Santangelo, & Crowe, 2010). 
The appropriation of HuR by different viruses suggests a proviral function for HuR and 
as such makes it an appealing target for examination during EBOV infection.  
 
Scientific Proposal  
The majority of studies dealing with the innate immune evasion strategies 
employed by EBOV focus on the type I IFN response.  Little is known regarding the 
interaction of EBOV with the host RNA regulatory machinery and the influence this has 
on viral replication. By defining the cellular events that take place during EBOV 
infection, we improve our understanding of EBOV pathogenesis. Furthermore, by 
identifying antiviral mechanisms that the virus is unable to disturb or evade we can 
identify putative targets for antiviral interventions and improve the development of 
therapeutic strategies. Here, investigated two mechanisms of host RNA regulation with 
antiviral implications during EBOV infection. These include the cellular stress response 
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mediated by SG formation and the post-transcriptional control of mRNA stability. This 
dissertation is divided into two main research topics based on these separate but related 
research aims.  
 
Part I: The Cellular Stress Response 
While type I IFNs and cytoplasmic pattern recognition receptors are thought of as 
prototypical components of the host innate antiviral response, the cellular stress response 
is becoming increasingly appreciated as an important antiviral strategy (Montero & 
Trujillo-Alonso, 2011; J. P. White & Lloyd, 2012). Central to this response is the rapid 
repression of cellular translation to prioritize the production of proteins important for cell 
survival. Because viral protein synthesis relies on the host translation machinery, 
translational arrest mediated by SG formation is an efficient strategy for inhibiting viral 
replication and as such, many viruses have evolved mechanisms to overcome this block. 
To date, no studies have examined the cellular stress response and potential antiviral 
implications it might have during EBOV infection. While it has been shown that EBOV 
is able to antagonize the dsRNA sensor PKR, these studies did not examine PKR’s 
function as an inducer of SG formation. Furthermore, PKR antagonism was only 
examined late in infection, providing no insight into whether EBOV may be able to 
prevent SG formation and avoid translational repression early in infection.  Therefore, it 
is undetermined if SG formation occurs at any point during EBOV infection, or whether 
the stress response influences EBOV replication. Additionally, it is unknown if EBOV is 
able to prevent the activation of the other eIF2α kinases, which could represent 
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alternative mechanisms for inducing the stress response and thereby repressing viral 
translation. In Chapter 3 we investigated whether SG formation occurs at any time during 
the course of infection, and if EBOV is able to block this response. Furthermore, we 
aimed to determine if EBOV interferes with SG formation induced by other forms of 
stress, aside from viral infection, to identify potential antiviral pathways that the virus is 
unable to evade.  
 
Part II: Post-transcriptional control of mRNA stability 
   Fatal EBOV infection is characterized by an uncontrolled inflammatory response 
and cytokine storm (Baize et al., 2002; Feldmann & Geisbert, 2011b; Wauquier, 
Becquart, Padilla, Baize, & Leroy, 2010). It is still unclear, however, what the 
mechanisms are that lead to such a discordant and dysfunctional immune response. 
Cytokines and chemokines make up a significant portion of cellular proteins that can be 
regulated at the mRNA level by AREs and ARE-BPs (Anderson, 2010). The viral protein 
VP30 is an RNA-binding protein that shares many similarities, including a CCCH zinc 
finger motif, to cellular proteins known to function as mRNA destabilizing factors (John 
et al., 2007; Modrof et al., 2003). TTP, BRF1 and ZAP all contain CCCH zinc finger 
motifs and mediate the degradation of their targets via AREs (Lai et al., 2000). Therefore, 
in Chapter 4 we investigated whether VP30 functions as an ARE-BP and contributes to 
the dysregulation of cytokines observed during infection.  
The EBOV genes contain unusually long 5’ and 3’ UTRs flanking the open reading 
frames. Four of the seven EBOV genes contain putative AREs within the 3’UTRs of the 
  
31 
corresponding mRNAs. It is not known whether these 3’UTRs influence viral mRNA 
stability. Here, we aim to elucidate the function of the putative AREs on viral mRNA 
stability and determine their impact on viral protein translation. It is conceivable that 
VP30 targets ARE-containing viral mRNAs to regulate their stability and translation, and 
to control the amount of viral mRNA that is present in cells. The putative AREs within 
viral 3’UTRs might also influence mRNA stability independently of VP30 and instead be 
targeted by cellular ARE-BPs, a phenomenon that has been observed for a growing 
number of viruses (Dickson & Wilusz, 2011; Sokoloski et al., 2010). Therefore, we 
aimed to identify whether VP30 functions as an ARE-BP and regulates the stability of 
potential viral and cellular mRNA targets, such as cytokines known to be dysregulated 
during EBOV infection. We also aimed to determine whether VP30, which is required for 
viral transcription, regulates the stability of EBOV mRNAs by targeting the putative 
AREs in their 3’UTRs.  
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CHAPTER TWO: MATERIALS AND METHODS 
Cell Culture 
Cells were maintained in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), penicillin (50 units/ml), and 
streptomycin (50 mg/ml) and L-glutamine (200 mM) unless otherwise noted. U2OS-
USP10-eGFP cells were treated with 200 ng/ml doxycycline (Sigma) 24 hours prior to 
infection or transfection to induce USP10-eGFP expression.  THP-1 cells were grown in 
suspension in RPMI media.  Prior to use, cells were matured by seeding 5 x 10^5 cells 
per well in a 6 well plate in 2 ml RPMI media supplemented with 100 nM phorbol 
myristate acetate (PMA).  Cells were matured over 2 days at 37 oC. Two days after 
incubation with PMA, media was replaced with 2 ml fresh RPMI media and incubated 
for 2 more days at 37 oC.  A list of all eukaryotic cells lines used is outlined in Table 1. 
Table 1. Eukaryotic Cells Lines  
Name Cell type From 
HEK293T Human embryonic kidney, 
epithelial  
G. Viglianti, Boston University  
HuH7 Human hepatocellular 
carcinoma, epithelial  
J. Alonso, Texas Biomedical 
Research Institute, San Antonio, 
TX 
HeLa Cervical adenocarcinoma, 
epithelial  
ATCC CCL-2 
VeroE6 African green monkey kidney 
cells,  
ATCC CRL-1586 





Human osteosarcoma, epithelial, 
doxycycline inducible USP10-
eGFP overexpression 
N. Kedersha, Division of 
Rheumatology, Immunology and 




Human osteosarcoma, epithelial, 
stably overexpressing G3BP-
eGFP 
N. Kedersha Division of 
Rheumatology, Immunology and 
Allergy. Brigham and Women’s 
Hospital 
THP-1 Monocyte  R. Gummuluru, Boston University 
 
Viruses 
Zaire ebolavirus (EBOV; Kikwit or Mayinga isolate, Table 2) was grown in Vero 
or VeroE6 cells and virus titers were determined by TCID50 or plaque assay. All work 
with EBOV was done under biosafety level 4 conditions at the Integrated Research 
Facility in the Rocky Mountain Laboratories, Division of Intramural Research, NIAID, 
NIH, Hamilton, MT, or the Texas Biomedical Research Institute San Antonia, Texas. 
BSL-4 infections were performed by: Dr. Judith Olejnik, Dr. Adam Hume, Dr. Kristina 
Schmidt, Dr. Laure Deflubé-Owen, or Dr. Logan Banandyga  
Table 2. Virus Isolates  
Virus Source Genbank # 
Zaire ebolavirus (Mayinga 
1976 isolate ) 
Center for Disease Control and 
Prevention (CDC), Atlanta GA, USA 
AF086833.2 
Zaire ebolavirus (Kikwit 1995 
isolate)  
National Institutes of Allergy and 
Infectious Disease (NIAID), Rocky 





Molecular Cloning of 3’UTRs into pMIR-Luciferase Reporter  
To insert the individual 3’UTRs (positive-sense orientation) from the four viral 
nucleocapsid mRNAs into the pMIR-luciferase reporter plasmid (Origene), the 3’UTRs 
from the NP, VP30 and VP35 genes were excised from existing pTM1 expression 
plasmids using appropriate restriction enzymes. The 3´ UTR specific regions were then 
amplified by PCR using the primers outlined in Table 4. All PCR reactions were 
performed using the PfuUltra Hotstart DNA polymerase (Agilent, #600390) and were 
performed as recommended by the manufacturer. The 3’UTR of the VP24 gene derived 
from EBOV Mayinga genomic RNA. For RNA isolation, VeroE6 cells were infected 
with EBOV and cell supernatants containing EBOV particles were collected four days 
post infection and cleared of debris by a low-speed centrifugation step. Viral genomic 
RNA was purified using the Qiagen QIAamp viral RNA mini kit.  The 3’UTR of the 
VP24 gene was then reverse transcribed and amplified using the specific primers listed in 
Table 4, with the Qiagen OneStep RT-PCR kit.  All viral 3’UTRs were PCR-amplified a 
second time to add terminal restriction sites for the restriction enzymes SpeI and HindIII 
(primers outlined in Table 5). The newly amplified DNA of all 3’UTRs were purified 
using a PCR purification kit (Qiagen) and then individually ligated into the pMIR-
luciferase reporter plasmid. The resulting plasmids were transformed into high efficiency 
competent E.coli (New England Biolabs) and cloned and amplified using standard 
procedures. For insertion of the 3’UTRs of IL-10 and TNF-α genes into the pMIR-
luciferase reporter plasmid, cellular mRNA was isolated from THP-1 cells, matured with 
100 nM PMA.  Cells were matured for 2 days at 37 oC, and then treated with 200 ng/ml 
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LPS (InvivoGen) for 2 hours. RNA was isolated using RNAzol (Molecular Research 
Center Inc.) following the manufacturer’s protocol for mRNA isolation. Insertion of these 
3’UTRs and cloning of the resulting plasmids was performed as described for the VP24 
3’UTR.   
Table 3. Plasmids  
Name Source 
3E-5E-Luciferase  Mühlberger Lab 
3E5E-eGFP  Mühlberger Lab 
3E5E-mCherry Mühlberger Lab 
pCAGGS-eGFP Mühlberger Lab 
pCAGGS-L synth minus Mühlberger Lab 
pCAGGS-L Mühlberger Lab 
pCAGGS-NP full 3’UTR Generated by E.V.Nelson 
pCAGGS-NP no 3’UTR  Generated by E.V.Nelson 
pCAGGS-NP Mühlberger Lab 
pCAGGS-T7 (RNA-dependent DNA T7 
polymerase)  
Y. Kawaoka, University of Wisconsin, 
Madison, WI 
pCAGGS-VP24 Mühlberger Lab 
pCAGGS-VP30 Mühlberger Lab 
pCAGGS-VP35-HA Mühlberger Lab 
pCAGGS-VP35 Mühlberger Lab 
pCDNA3- HuR Kindly provided by N. Kedersha  
pCDNA3-VP35-3A Mühlberger Lab 
pCDNA3-VP35-Del3 Mühlberger Lab 
pCDNA3-VP35-Del4 Mühlberger Lab 
pCDNA3-VP35-Del7 Mühlberger Lab 
pCDNA3.1- TTP-Myc/His Generated by E.V.Nelson,  
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pCMV-SPORT-TTP Purchased from Harvard Plasmid 
Repository 
pMIR-Beta-galactosidase Purchased from Origene 
pMIR-IKB-α Purchased from Origene 
pMIR-IL-10 Generated by E.V.Nelson 
pMIR-IL-6 Generated by E.V.Nelson 
pMIR-Luciferase Generated by E.V.Nelson 
pMIR-NP  Generated by E.V.Nelson 
pMIR-TNF-α Generated by E.V.Nelson 
pMIR-VP24 Generated by E.V.Nelson 
pMIR-VP30 Generated by E.V.Nelson 
pMIR-VP35 Generated by E.V.Nelson 
 
Table 4. 3’UTR Cloning Primers Initial RT-PCR 
 
 


























Table 5. 3’UTR Cloning Primers 
 
Table 6. Primers: Altering NP 3’UTR Lengths in pCAGGS Backbone 









































 Table 7. Sequencing Primers 
 
Quantitative reverse transcription-PCR (qRT-PCR) 
Total cellular RNA was isolated from 293T cells using RNAzol (Molecular 
Research Center, Inc), as directed by the manufacturer. Five ng of RNA were then 
analyzed by qRT-PCR using the QuantiFast SYBR green RT-PCR kit (Qiagen) following 
the manufacturer’s protocol. Validated primers by Qiagen were used (QuantiTect primer 
assays) to detect and quantify IL-6, TNF-α, HuR, TTP, or β-2-microglobin RNA.  
Primers designed by E.V. Nelson were used to detect and quantify luciferase, eGFP, NP 
and IL-6 RNA levels (Table 8). β-2-microglobin was used as an endogenous control for 
normalization.  Data was collected and analyzed using the ΔΔCT method with Bio-Rad 
























Table 8. qRT-PCR Primers Designed by E.V. Nelson 
Target Forward Reverse 
eGFP GACGTAAACGGCCACAAGTT AAGTCGTGCTGCTTCATGTG 
IL-6 CATCACTCGAGCAATTTGGA TGTTTGTGGACGAAGTACCG 







All transfections were performed using the lipid based transfection reagents, 
transIT-LT1 (Mirus), Lipofectamine LTX with Plus reagent (Invitrogen), or 
Lipofectamine 2000 (Invitrogen) following the manufacturer’s protocols.  Cells were 
transfected at between 60-70% confluency. For those transfections done using with 
transIT-LT1, media was removed before transfection and replaced with DMEM 
supplemented with 2% FBS and L-glutamine (200 mM). 
 
Luciferase Assay 
pMIR-luciferase reporter plasmids along with a beta-galactosidase (B-gal) 
expression plasmid (see below) were transfected into 293T cells seeded at a density of 
3x10^5 cells per well in 6-well or 1.5X10^ 5 cells per well in 12-well plates using the 
transIT LT1 transfection reagent as described above. Cells were harvested two days post 
transfection using 1X cell lysis buffer (CLB) (Promega, catalog #E1500). Prior to lysis, 
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cells were washed once with 1 ml of PBS at room temperature.  For lysis in a 6-well 
plate, 600 of µl 1X CLB per well were added onto the cells and incubated for 20 minutes 
at room temperature with gentle shaking.  For lysis in 12-well plates, 300 µl 1X CLB 
were added per well. After lysis, samples were transferred to 2 ml Eppendorf tubes and 
subjected to centrifugation at 12,000 x g at 4oC for 5 minutes.  Supernatants were then 
transferred to 1.5 ml Eppendorf tubes and either immediately assayed for luciferase 
activity, or stored at -20oC until ready for use.  The luciferase assay was performed in 96-
well format with a LUMIstar Omega luminometer (BMG Labtech) using 20 µl of the 




All luciferase assay samples were normalized to B-gal activity (B-gal). 50 µl of 
cell lysates were used for a B-gal enzyme system assay (Promega) in 96-well format 
following the manufacturers protocol.  Samples were read on Molecular Devices Spectra 
Max M2 plate reader.           
 
Minigenome System 
The EBOV minigenome assay was performed in 293T or U2OS cells as 
previously described (Mühlberger et al., 1999; Trunschke et al., 2013). 293T cells were 
transfected with a pCAGGS-T7 plasmid, along with T7 RNA polymerase-driven pTM1 
plasmids encoding the EBOV NP, VP35, VP30 and L genes. In addition, cells were also 
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transfected with a T7-driven plasmid expressing the EBOV 3E-5E minigenome 
containing the reporter genes eGFP or luciferase, in negative sense. U2OS cells were 
transfected with support plasmids in the pCAGGS backbone, and a 3E-5E-eGFP 
minigenome under the control of a Pol II promoter. 
 
Western Blot Analysis 
Preparation of EBOV-Infected Cell Lysates 
At the indicated time points post infection, EBOV-infected and mock-infected 
cells were scraped into 5 ml ice cold PBS, transferred into a 15 ml tube and subjected to 
centrifugation for 10 min at 500 x g. All liquid was removed and the pellet was frozen at 
-20oC until ready for lysis. For cell lysis, the frozen pellet was resuspended in 25 µl cell 
extraction buffer (Invitrogen) supplemented with 1 µl protease inhibitor (Roche) and 0.25 
µl phosphatase inhibitor (HALT, Pierce). The lysates were transferred to a 1.5 ml tube 
and left on ice for 20 minutes, vortexing every 5-7 minutes during this incubation period.  
Samples were centrifuged for 8 min at 10,600 x g and 25 µl of the lysates were 
transferred into fresh tubes containing 4x SDS sample buffer and incubated for 10 min at 
99°C to inactivate EBOV. 
 
Preparation of Transfected Cell Lysates 
  Transfected cells were harvested for Western blot analysis at the indicated times 
post transfection. Cells were scraped into cell culture media, transferred to 2 ml tubes, 
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and spun down at 15,000 x g for 3 minutes at 4oC. Supernatants were discarded and the 
pellet was resuspended in 50 µl cell extraction buffer (Biosource) complemented with 1 
mM protease inhibitor mix (Complete; Roche) and 0.1 µM serine/threonine phosphatase 
inhibitor (calyculin A; Cell Signaling Technologies). Lysates were incubated for 20 
minutes on ice, vortexing briefly during this time.  The lysates were then centrifuged for 
10 minutes at 15,000 x g at 4oC.  Supernatants were transferred to 1.5 ml tubes containing 
50 µl 2X SDS-sample buffer (Laemmli Buffer) and either used for Western blot analysis 
immediately or stored at -20oC until ready for use.    
 
Detection of Proteins 
To detect proteins of interest by Western blot analysis, SDS-PAGE gels were 
prepared as outlined in Table 9.  Prior to loading, samples were incubated for 5 minutes 
at 95oC. SDS gels were then loaded with the appropriate volume of sample and run at 
100-140 volts until sufficient separation of proteins occurred.  After separation, the 
proteins in the SDS-PAGE gel were transferred to a polyvinylidene fluoride (PVDF) 
membrane.  The membrane was activated by incubating it for 30 seconds in 100% 
methanol. Transfer was performed by placing the SDS-PAGE gel and PVDF membrane 
between separate layers of Whatman blotting paper soaked in three separate transfer 
buffers (anode I, anode II, and cathode buffers, respectively). Proteins were transferred at 
30 volts for 30 minutes.  After transfer, the membrane was incubated in blocking buffer 
(Odyssey Blocking Reagent) for 1 hour at room temperature, or 4oC overnight, then 
washed 3 times in TBS + 0.1% Tween, for ten minutes per wash.  The membrane was 
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then incubated with the appropriate primary antibodies, diluted in Odyssey Blocking 
Reagent supplemented with 0.1% Tween for either 1 hour at room temperature or 4oC 
overnight.  Primary antibodies used are outlined in Table 10. After the membrane was 
washed three times with TBS supplemented with 0.1% Tween, 10 minutes per wash, it 
was incubated with the appropriate secondary antibodies diluted in Odyssey Blocking 
Reagent with 0.1% Tween for either 1 hour at room temperature or 4oC overnight. The 
membranes were protected from light and washed twice in TBS with 0.1% Tween, 
followed by two washes with TBS alone.  Blots were then scanned on the Odyssey 
Infrared Imaging system, and analyzed using Image Studio software. 
 
Table 9. Preparation of SDS-PAGE Gels  
 Stacking gel Separating gel 
 4% 8% 10% 12% 
H2O 2.9 ml 4.7 ml 4 ml 3.3 ml 
30% 
acrylamide/bisacrylamide 
750 µl 2.6 ml 3.3 ml 4 ml 
10% SDS 50 µl 100 µl 100 µl 100 µl 
1.5 M Tris pH 8.8 - 2.5 ml 2.5 ml 2.5 ml 
0.5 M Tris pH 6.8 1.25 ml - - - 
10% APS 50 µl  100 µl 100 µl 100 µl 







Table 10. Western Blot Primary Antibodies   
Target Species Source Dilution  
β-actin Mouse Abcam (ab8226-100) 1:1000 
eIF2α phospho Rabbit Life Technologies (44-728G) 1:1000 
eIF2α total Mouse Biosource (AHO802) 1:500 
Flag (M2) Mouse Sigma (F1804) 1:25,000 
HA Mouse  Covance (MMS-101P) 1:2000 
HuR Mouse Santa Cruz Biotechnology, Inc (sc-
5261) 
1:600 
Lamin B Rabbit Abcam (ab16048) 1:3000 
NP Mouse G. Olinger USAMRIID 1:5000 
TTP Rabbit P. Anderson, Division of 
Rheumatology, Immunology and 
Allergy. Brigham and Women’s 
Hospital 
1:1500 
Tubulin Mouse Sigma (T6199) 1:5000 
VP35 Mouse  C. Basler, Department of 
Microbiology, Icahn School of 





Fixation of EBOV-Infected Cells 
At the indicated times post infection, EBOV-infected cells grown on chamber 
slides (Thermo Scientific) or chambered glass slides (Fisher Scientific) were fixed and 
inactivated for at least 24 hours with 4% paraformaldehyde (PFA, v/v) at 4oC following 
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the inactivation SOPs of the respective BSL-4 facility. Once inactivated, all samples were 
treated as non-infectious and any subsequent immunofluorescence analysis (IFA) was 
performed at BSL-2 conditions.   
 
Fixation of Non-Infected or Transfected Cells 
At the indicated times post transfection, and after any appropriate drug treatments, 
media was removed from cell culture plates, and cells were washed once with PBS.  
Enough 4% PFA to cover the cells was then added, and cells were incubated at room 
temperature for 20 minutes, or 4oC overnight.  Transfection experiments intended for IFA 
were performed using glass coverslips.    
 
Immunofluorescence Analysis 
After fixation, PFA was removed and cells were washed with PBS.  Cells were 
then permeabilized with 0.1% Triton X 100 (Boston Bioproducts) for 5 minutes at room 
temperature, using just enough Triton X to cover the cells on the slides or on the 
coverslips. Samples were then washed three times with PBS and subsequently incubated 
with 0.1 M glycine in PBS for 5 minutes at room temperature.  Samples were again 
washed three times with PBS and then incubated with blocking reagent for 10 minutes at 
room temperature.  Chamber slides or coverslips were then incubated at 4oC overnight 
with the appropriate primary antibodies diluted in 25 µl blocking solution. All primary 
antibodies and their working dilutions are outlined in Table 11.  After overnight 
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incubation with primary antibodies, samples were washed three times with PBS, and 
incubated with the applicable secondary antibodies (Table 12) diluted in 25 µl blocking 
solution for 1 hour at room temperature, protected from light.  All chamber slides or 
coverslips were then washed three times in PBS dipped in Ultrapure water and dried 
slightly before fixing to glass microscope slides using mounting reagent (Calbiochem).  
Coverslips were sealed using nail polish around the edges.   
Table 11. Primary Antibodies for Immunofluorescence  
Target Species Source Dilution  
EBOV serum Goat S. Becker, University of Marburg, Marburg, 
Germany  
1:500 
eIF3 Goat Santa Cruz Biotechnology Inc., (sc-16377) 1:50 
eIF4G Rabbit Santa Cruz Biotechnology, Inc. (sc-11373) 1:100 
G3BP Mouse BD Biosciences (611126) 1:50 
HA Mouse Covance (MMS-101P) 1:50 
HA Rabbit  Covance (PRB-101P) 1:100  
HuR Mouse Santa Cruz Biotechnology Inc., (3A2) 1:50 
NP Mouse G. Olinger USAMRIID 1:100 
PABP Mouse Santa Cruz Biotechnology, Inc. (sc-32318) 1:50 
TIA-1 Goat Santa Cruz Biotechnology, Inc. (sc-1751) 1:50 
TTP Rabbit P. Anderson, Division of Rheumatology, 
Immunology and Allergy. Brigham and 
Women’s Hospital 
1:750 
USP10 Rabbit J. Connor, Boston University 1:200  
VP35 Mouse C. Basler, Department of Microbiology, 






Table 12. Secondary Antibodies for Immunofluorescence 
Fluorescence conjugate Species Target Species 
Alexa Fluor 350 Donkey Mouse 
Alexa Fluor 488 Chicken Mouse 
Alexa Fluor 488 Goat Rabbit 
Alexa Fluor 488 Donkey Goat 
Alexa Fluor 488 Goat Rabbit 
Alexa Fluor 350 Donkey Rabbit 
Alexa Fluor 594 Donkey Goat 
Alexa Fluor 594 Chicken  Mouse 
Alexa Fluor 647 Donkey Goat 
Alexa Fluor 647 Goat  Mouse 
Alexa Fluor 647 Donkey  Rabbit  
 
 
Induction of Stress Granule Formation 
For the induction of stress granule formation, cells were treated with 0.5 to 2 mM 
sodium arsenite (Ars) for 30 minutes at 37°C and then fixed in 4% PFA. For EBOV 
infection experiments, Ars treatment was performed by replacing media with fresh media 
either containing the indicated amount of Ars, or media without Ars for mock-treated 
cells. For transfection experiments, the indicated amount of Ars or PBS (mock-treated) 
was added dropwise onto the cells.  Hippuristanol (kind gift from J. Pelletier, McGill 
University, Montreal, Canada) was also used to induce SGs. 1.25 µM Hippuristanol 
(Hipp) or the same volume of PBS (mock-treated) was added dropwise onto the cells.  





U2OS cells were infected with EBOV at an MOI of 1.5 PFU per cell. At 24 hours 
p.i., cell supernatants were removed and replaced with DMEM supplemented with 2% 
FBS and 0.5 mM Ars or DMEM and FBS alone for mock treated cells. After a 30 minute 
incubation period at 37°C, supernatants were removed and replaced with media 
containing either 100 µg/ of cycloheximide (CHX) or DMSO. Cells were incubated for 
one hour at 37oC, washed once with PBS and fixed with DMEM containing 4% PFA.  
 
Fluorescence In-situ Hybridization (FISH) 
All FISH experiments were performed by Dr. S. Doganay at the Department of 
Physics, University of Illinois at Urbana-Champaign, IL. FISH probes were designed 
using Stellaris FISH Probe Designer software from Biosearch Technologies. A total of 48 
probes, each 20 nucleotides in length and labeled with Alexa Fluor 594 or Cy5 were used 
to target the EBOV NP mRNA or genomic RNA sequence. U2OS cells were infected at 
an MOI of 1 as described above in the IFA section. Cells were fixed with 4% PFA for 48 
hours and stored in 70% EtOH at -20°C until usage. Cells were rehydrated in PBS and 
subsequently subjected to FISH or IFA followed by FISH.  For immunofluorescence 
analysis (IFA), all reagents were supplied with 2 mM of vanadyl ribonucleoside complex 
(VRC). For permeabilization and blocking, the IFA protocol described above was used. 
Primary antibodies were incubated for 3 hours and secondary antibodies for 2 hours at 
room temperature. After antibody incubation, cells were treated with 3% PFA for 10 
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minutes at room temperature for post-fixation and subjected to FISH. For FISH, cells 
were washed in 2x SSC (0.3 M NaCl, 0.03 M sodium citrate) containing 10% formamide 
for 5 minutes. Hybridization was performed at 37˚C overnight in 100 µl of hybridization 
buffer (10% dextran sulfate, 2 mM VRC, 0.02% RNAse-free BSA, 50 µg E.coli tRNA, 
2x SSC, 10% formamide) containing labeled FISH probes targeting EBOV NP mRNA.  
 
Click-iT Metabolic Labeling Assay 
For fluorescence-based detection of nascent proteins, the Click-iT L-
homopropargylglycine (L-HPG) metabolic labeling system (Invitrogen) was used. U2OS 
cells were infected as described above. At 25 hours p.i., cells were washed with D2-
Met/Cys depletion medium (Sigma Gibco) and incubated in D2-Met/Cys depletion 
medium for one hour. Cell supernatants were removed and replaced with D2-Met/Cys 
depletion medium supplemented with 100 µM Click-iT L-HPG. After a 30-minute 
incubation period at 37oC, cells were fixed with 4% PFA as described above, 
permeabilized with methanol for 15 minutes at -20oC and blocked with 5% donkey serum 
for one hour. The Click-iT reaction buffer containing Alexa Fluor 488 detection reagent 
was added for 30 minutes at room temperature, protected from light. The cells were 
washed with 5% donkey serum, and then placed in PBS at 4oC until ready for further IFA 




Imaging and Processing 
Confocal imaging was performed using a Zeiss 710 confocal microscope with a 
Plan-Apochromat primary objective (63x; NA, 1.4). All images were taken using multi-
track scanning for each fluorophore to prevent bleed-through. Z-dimension (z-) stacks, 
pinholes were set to an Airy unit of 1. Images were also acquired with a Zeiss Axiovert 
200 M inverted microscope and a Plan-Apochromat primary objective (63x; NA, 1.4). 
Image acquisition and processing software used includes the Zeiss Zen (confocal 




For quantitative analysis of SG-containing cells, cells were counted by two 
independent researches. One researcher was unbiased to the experiment and blinded to 
the drug conditions. An unpaired two sample t-test was performed using the GraphPad 
Prism version 5.04 for Windows, GraphPad Software, La Jolla California USA, 
www.graphpad.com.   
 
Buffer Recipes 
Blocking Reagent for IFA 
20 g Bovine Serum Albumin (BSA), 2 ml Tween-20, 30 ml glycerin, 10 ml sodium azide 
(NaN3, 5% solution), 1 L sterile PBS, sterile filtered  
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0.1 M Glycine for IFA 
3.75 g glycine and 500 ml Ultrapure H2O 
0.1% Triton for IFA 
0.1 ml Triton-X-100 and 100 ml PBS 
4% Paraformaldehyde for IFA 
71.25 ml 32% PFA solution and 500 ml DMEM 
SDS-PAGE Running Buffer (10x) 
10 g SDS, 30 g Tris, 144 g glycin, and 1 L H2O 
10% SDS for Western Blot 
50 g SDS and 500 ml H2O 
TBS (10x) for Western Blot 
24.2 g Tris, 80 g NaCl, 1 L H2O, the pH was adjusted to 7.6 with HCl 
1.5 M Tris for SDS gels 
181.71 g Tris and 1 L H2O, the pH was adjusted to  to 8.8 or 6.8 with HCl 
Anode Buffer I for Western Blot 
36.34 g Tris, 200 ml EtOH, and 1 L H2O 
Anode Buffer II for Western Blot 
3.06 g Tris, 200 ml EtOH, and 1 L H2O 
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Cathode Buffer for Western Blot 




CHAPTER THREE: EXAMINING THE CELLULAR STRESS RESPONSE 
DURING EBOLA VIRUS INFECTION 
 
Rationale 
During EBOV infection, the virus employs many immune evasion strategies, most 
notably via multiple layers of type I interferon (IFN) inhibition. VP35 is a key player in 
this innate immune evasion but also acts as a nucleocapsid component and a polymerase 
cofactor (Audet & Kobinger, 2015; Basler, 2015). By binding to and masking dsRNA, 
VP35 is able prevent the activation of viral nucleic acids sensors such as retinoic acid 
inducible gene 1 (RIG-I) (Cárdenas et al., 2006). Furthermore, VP35 has been shown to 
antagonize both PKR and IRF-3 activity, contributing to IFN inhibition (Feng, Cerveny, 
Yan, & He, 2007a; Hartman et al., 2004; Prins et al., 2009; Schümann et al., 2009). 
While type I IFNs and cytoplasmic nucleic acid pattern recognition receptors are thought 
of as prototypical components of the host innate antiviral response, the cellular stress 
response has also been implicated as an important mechanism for halting viral protein 
translation and thereby limiting viral replication (Montero & Trujillo-Alonso, 2011; 
Onomoto, Yoneyama, Fung, Kato, & Fujita, 2014).  The global decrease in protein 
translation associated with SG formation is unsustainable for viral replication, which 
requires the host translational machinery to synthesize viral proteins. Therefore, many 
viruses have evolved strategies to antagonize the induction of the stress response. This 
often involves a disruption in the signaling pathways leading to eIF2α phosphorylation, 
primarily via PKR antagonism (Montero & Trujillo-Alonso, 2011; Valiente-Echeverría, 
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Melnychuk, & Mouland, 2012). Other mechanisms observed include the degradation or 
sequestration of key SG nucleation proteins such as G3BP or TIA-1(Matthews & Frey, 
2012; J. P. White & Lloyd, 2011).  
While many viruses have been shown to disrupt SG formation at various times 
during infection, little is known about the induction of a stress response during EBOV 
infection and whether the virus possesses putative SG antagonizing functions to prevent 
SG formation. It has been shown previously that PKR activation, the main trigger for SG 
induction during viral infection, is suppressed in EBOV-infected cells by VP35 through 
an undefined mechanism (Feng, Cerveny, Yan, & He, 2007a; Schümann et al., 2009). 
Furthermore, eIF2α is not phosphorylated during EBOV infection, suggesting that SG 
formation is not induced (Olejnik et al., 2013). However, the inhibitory effects of 
VP35on PKR activation were observed late in infection when the amount of VP35 was 
presumably high. It is thus unknown if PKR activation and eIF2α phosphorylation occur 
early in infection, when the VP35 levels are still low. Vulnerability of EBOV to 
exogenous stress might reveal novel strategies toward the development of antivirals. 
Therefore, we aimed to examine the cellular stress response mediated by SG formation 
more thoroughly during EBOV infection.  
 
Results 
3.1 Stress granules do not form during EBOV infection. 
To determine if SG formation is induced during EBOV infection, particularly at 
early time points, we analyzed the distribution of the SG proteins eIF4G (Figure 3) and 
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TIA-1 (Figure 4) in EBOV-infected U2OS cells at different time points post infection 
(p.i.) by IFA. In non-infected cells, both eIF4G and TIA-1 were homogenously 
distributed in the cytoplasm at all time points examined, but were redistributed into 
typical punctate SGs when sodium arsenite (Ars) was used to induce oxidative stress 
(Figures 3 and 4, right panels). In EBOV-infected cells at early time points p.i. eIF4G and 
TIA-1 showed similar homogenous distribution in the cytoplasm and SGs were not 
observed. EBOV infection, visualized by staining for the nucleocapsid protein VP35, 
could only be detected at 17 and 24 hours p.i. when viral protein expression was high. At 
these late time points VP35 staining denoted typical viral inclusion formation, while 
eIF4G and TIA-1 were homogenously distributed throughout the cytoplasm of infected 
cells. Staining for another canonical SG protein eIF3 (data not shown) also indicated that 
SG formation did not occur at any time examined during EBOV infection.  Collectively, 
the homogenous distribution of these canonical SG proteins in the cytoplasm of EBOV 





Figure 3. EBOV infection does not induce eIF4G containing canonical SGs.   
U2OS cells were infected with EBOV at an MOI of 1 or mock-infected. At the indicated 
time points p.i. mock-infected cells were treated with 0.5 mM Ars (+Ars) for 30 minutes 
to induce SG formation or left untreated (-Ars). IFA was performed using antibodies 




Figure 4. EBOV infection does not induce TIA-1 containing canonical SGs. 
U2OS cells were infected with EBOV at an MOI of 1 or mock-infected. At the indicated 
time points p.i. mock-infected cells were treated with 0.5 mM Ars (+Ars) for 30 minutes 
to induce SG formation or left untreated (-Ars). IFA was performed using antibodies 
against VP35 (red) and TIA-1 (green).   
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3.2 SG proteins are sequestered within viral inclusions late during infection. 
 Although eIF4G was homogenously distributed throughout the cytoplasm of 
infected cells, indicating that SGs do not form, it was found aggregated within the viral 
inclusions starting at 17 hours p.i. in EBOV infected cells (Figure 3). This accumulation 
of eIF4G was more pronounced at 24 hours p.i. when viral inclusions were larger and 
more prominent (Figure 3). Many other SG proteins, including eIF4G (Figure 5A i), eIF3 
(Figure 5A ii), poly-A binding protein (PABP Figure 5A iii) and human antigen R (HuR, 
Figure 5A iv), were found sequestered within viral inclusions by 24 hours p.i. but 
otherwise remained homogenously distributed throughout the cytoplasm. While a number 
of SG proteins were found aggregated within viral inclusions, the homogenous 
distribution of TIA-1 in both the nucleus and cytoplasm of EBOV-infected cells 
demonstrated that not every canonical SG protein was sequestered in viral inclusions. 
TIA-1 distribution looked similar to that found in non-infected cells, and showed little 
accumulation within viral inclusions (Figure 5B).  There were however, small clusters 
that appeared to show minor aggregation similar to that observed for other proteins 
(Figure 5B, white arrows).  Similar to TIA-1, ubiquitin carboxyl-terminal hydrolase 10 
(USP10) did not aggregate within viral inclusions, although there were also minor areas 
of weak colocalization (Figure 5C, white arrows).  Finally, the SG protein TTP, which is 
an important regulator of mRNA stability, was also absent from viral inclusions (data not 
shown).  However, TTP showed no minor aggregation or colocalization with viral 
inclusions, suggesting that it is entirely excluded from inclusions.  Collectively these data 
indicate that many, but not all, SG proteins are sequestered within viral inclusions at late 
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times during infection. Furthermore, these SG protein granules are compositionally 
different from fully formed canonical SGs and might represent a distinct species of 
protein granules. 
 To further examine the distribution of the SG proteins within viral inclusions, 
optical sectioning was performed in order to obtain Z-stack images of multiple focal 
planes within a single EBOV inclusion.  This type of analysis allows users to examine 
protein colocalization in three dimensions, as depicted in (Figure 6, top panel), which 
helps remove some of the limitations of examining 3D structures images in two 
dimensions.  When EBOV infected U2OS cells were examined using this technique, we 
observed that the SG proteins sequestered within viral inclusions showed no direct 
colocalization with any nucleocapsid protein, and that viral proteins were excluded from 
these aggregates (VP35 examined in red, eIF4G in green, Figure 6 bottom panel).  
Together, these results indicate that the nucleocapsid proteins fully encompass, but are 






Figure 5. SG proteins are sequestered within viral inclusions.  
A) U2OS cells were infected with EBOV at an MOI of 1.5, fixed at one day p.i. and 
analyzed by IFA. The SG proteins (green) eIF4G (i), eIF3 (ii), PABP (iii) or HuR (iv) 
were examined using antibodies specific for each protein. EBOV inclusions (red) were 
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detected using either an antibody against VP35 (i, ii) or an anti-EBOV serum that 
recognizes both GP and NP (iii, iv). B) U2OS cells were infected as in (A) but were 
stained for the viral protein VP35 (red) or the SG protein TIA-1 (green). White arrows 
indicate areas of TIA-1 minor colocalization with viral inclusions. C) U2OS cells were 
infected as in (A) but were stained for the viral protein NP (red) or the SG protein USP10 
(green). White arrows indicate areas of USP10 minor colocalization with viral inclusions.  





Figure 6. Three-dimensional analysis of sequestered proteins in viral inclusions. 
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U2OS cells were infected with EBOV at an MOI of 1 and fixed at one day p.i. and 
stained for the viral protein VP35 (red) and SG protein eIF4G (green). Optical sectioning 
using confocal z-stack analysis was performed.  Schematic representation of the 
orientation of axes during optical sectioning is outlined in the top panel.  Bottom panel 




3.3 Sequestered SG proteins analyzed colocalize within viral inclusions. 
 To address whether the sequestered SG proteins colocalized within EBOV 
inclusions or if they formed discrete aggregates, EBOV-infected U2OS cells were fixed 
at one day p.i. and co-stained for different combinations of SG proteins. The proteins 
eIF3 and eIF4G colocalized within viral inclusions, suggesting that they were both part of 
the same inclusion-bound aggregates (Figure 7A, top panels). Likewise, PABP and 
eIF4G also colocalized within inclusions (Figure 7A, bottom panels). Interestingly, 
although HuR was found sequestered within viral inclusions, it showed a distinct 
aggregation pattern compared to the other SG proteins present (Figure 5A iv). Compared 
to the eIF3 and eIF4G-containing granules, HuR clusters were significantly smaller and 
exhibited more irregular and less punctate aggregation within inclusions. Co-staining for 
eIF3 and HuR in EBOV-infected U2OS cells confirmed that these proteins formed 
distinct granules in EBOV inclusions and did not colocalize (Figure 7B). The HuR 
aggregates found in inclusions in EBOV-infected cells were in close proximity to, but 
separate from eIF3 granules. Thus, while a majority of the SG proteins sequestered 
within inclusions were found to be components of the same aggregates, this did not hold 





Figure 7. SG proteins colocalize within inclusions.   
U2OS cells were infected with EBOV at an MOI of 1.5, fixed at one day p.i. and 
analyzed by IFA.  A) Colocalization of SG proteins within inclusions was examined 
using antibodies against eIF4G (red) and eIF3 (green), or eIF4G (red) and PABP (green) 




3.4 Inclusion formation is not sufficient to sequester SG proteins within inclusions. 
 To understand the driving force behind the accumulation of cellular proteins 
within viral inclusions, we next examined whether inclusion formation alone was 
sufficient to sequester SG proteins. U2OS cells were transfected with different 
combinations of plasmids expressing EBOV nucleocapsid proteins to induce inclusion 
formation in the absence of viral replication. In cells expressing NP alone, although 
inclusion formation was observed, eIF4G remained homogenously distributed in the 
cytoplasm and did not form aggregates within the inclusion-like structures (Figure 8).  
When NP was co-expressed in combination with the other nucleocapsid proteins, 
inclusions were reflective of those that form during infection, but eIF4G was never found 
aggregated within inclusions.  Therefore, inclusion formation alone is not sufficient to 
sequester SG proteins within inclusions.              
 To examine if viral RNA synthesis or polymerase activity is required to 
redistribute SG proteins into inclusions, we next employed the minigenome system 
(outlined in Figure 9).  This system can be used to mimic EBOV replication and 
transcription in a BSL-2 setting.  The EBOV minigenome consists of a reporter gene 
flanked by the 3’leader and 5’trailer regions of the EBOV genome. The minigenome 
contains all required sequence elements to be accepted as a template for replication and 
transcription by the EBOV polymerase (Mühlberger et al., 1999). Briefly, cells are 
transfected with an expression plasmid containing the minigenome along with support 
plasmids encoding the EBOV proteins required for replication and transcription, which 
include the nucleocapsid proteins NP, VP30 and VP35, and the polymerase L. Reporter 
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gene expression is indicative of proper viral replication and transcription (Hoenen et al., 
2012b; Mühlberger et al., 1999).  Using this system, U2OS cells were transfected with a 
3E5E-GFP minigenome driven by a pol II promoter, and the appropriate support 
plasmids, which were expressed from the pCAGGs backbone. Cells transfected in the 
absence of L showed no GFP expression as expected, and the SG proteins examined 
(HuR, G3BP and eIF4G) were all homogenously distributed in the cytoplasm, similar to 
their distribution in untransfected cells (data not shown).  Similarly, when L was co-
transfected with the minigenome and support plasmids, although GFP expression 
signified efficient minigenome activity, HuR, G3BP and eIF4G were not observed within 
viral inclusions and remained diffusely spread throughout the cytoplasm (Figure 10). 
These data indicate that inclusion formation and polymerase activity were not sufficient 






Figure 8. Inclusion formation is not sufficient to sequester SG proteins. 
U2OS cells were transfected with the indicated combinations of the expression plasmids 
containing the viral genes NP, VP30, VP35 or VP24 and examined 2 days post-







Figure 9. EBOV minigenome system.   
The 3’ and 5’ leader and trailer regions of the EBOV genome are cloned into a pol II-
driven expression plasmid where they flank a reporter gene. This expression plasmid is 
transfected into cells along with additional support plasmids, which encode the 
nucleocapsid proteins that are required for EBOV replication and transcription and 
include NP, VP35, L and VP30.  In the transfected cells, an RNA minigenome template 
is generated and the nucleocapsid proteins are expressed.  This then leads to initial rounds 
of replication, producing anti-minigenome, which is used as a template for additional 
minigenome production. Transcription of the minigenome leads to reporter gene mRNA 
production, followed by protein expression, which is the readout for successful 




Figure 10. EBOV minigenome replication and transcription are not sufficient to 
sequester SG proteins.  
 U2OS cells were transfected with the 3E-5E-eGFP minigenome, driven by a pol II 
promoter along with EBOV support plasmids.  Cells were fixed 2 days post transfection 
and examined by IFA.  Staining was performed for the SG proteins HuR, G3BP or eIF4G 
(red).  GFP expression indicates minigenome replication and transcription. Cells stained 
for eIF4G were also stained for the viral protein NP (blue) to identify viral inclusions. 
Scale bars = 20 µM   
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3.5 Sequestered SG proteins colocalize with viral RNA in inclusions 
Many of the proteins involved in SG formation are RNA binding proteins 
important for mRNA stability and translation initiation (Kedersha & Anderson, 2002).  
Because EBOV inclusions are the sites of viral RNA synthesis and contain viral RNA 
(Hoenen et al., 2012), we next examined if there was any interaction between the 
inclusion-bound SG proteins and viral RNAs within inclusions. To visualize the 
intracellular distribution of viral RNA species during infection, we performed fluorescent 
in-situ hybridization (FISH). U2OS cells were infected with EBOV and 24 hours p.i, 
examined by FISH analysis using probes specific for NP positive-sense mRNA or 
negative-sense genomic RNA. While the probes designed to target NP mRNA also 
recognize positive sense antigenome RNA, this RNA species is much less abundant in 
infected cells than the viral mRNA (Shabman et al., 2014; Weik, Enterlein, Schlenz, & 
Mühlberger, 2005). Therefore, we assume that FISH probes for NP positive-sense RNA 
are predominately targeting NP mRNA. At 6 hours p.i., NP positive-sense RNA was 
diffusely distributed throughout the cytoplasm of infected cells, but demonstrated 
clustered aggregation at 24 hours p.i. (Figure 11A). These aggregates resembled those 
observed for the SG proteins sequestered within inclusions. The distribution of negative-
sense genomic RNA showed similar aggregated distribution in a majority of cells 
examined at 24 hours p.i. (Figure 11B, left panel yellow arrows). However, it was also 
found in more inclusion-like patterns, with little to no aggregation apparent (Figure 11B, 
right panels, white arrows). When examined concurrently at 24 hours p.i., both positive-
sense NP RNA and negative-sense genomic RNA were found to colocalize in distinct 
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areas of infected cells, presumed to be inclusions (Figure 11C).  Staining for both 
negative-sense RNA and the viral protein NP confirmed that these RNA species were in 
fact found within viral inclusions (Figure 11D).   
 To examine if SG proteins colocalized with viral RNA, the SG protein eIF3 was 
stained for in addition to viral RNA.  At 24 hours p.i., both NP positive-sense RNA 
(Figure 12A) and negative-sense genomic RNA (Figure 12B) showed colocalization with 
eIF3. Positive-sense NP RNA showed no colocalization with TTP, however (Figure 
12C), suggesting that only the SG proteins found within inclusions colocalized with the 
viral RNA, and excluding the possibility of fluorescence bleed through.  Collectively, 
these data indicate that viral RNA colocalizes with inclusion-bound aggregates and may 





Figure 11. NP mRNA and genomic RNA colocalize within viral inclusions.  
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U2OS cells were infected with EBOV at an MOI of 1, fixed at 6 hours (A) or 24 hours 
p.i. (A-D) and analyzed by FISH using RNA probes specific for NP positive-sense RNA 
(A) or negative-sense genomic RNA (B). Yellow arrowheads in (B) indicate viral RNA 
with aggregated distribution similar to the distribution observed for inclusion bound SG 
aggregates.  White arrows indicate viral RNA with a more inclusion like distribution. C) 
Distribution of EBOV RNA in infected cells at 24 hours p.i. Positive-sense NP RNA is 
shown in green and negative-sense genomic RNA in red. Areas shown in higher 
magnification are indicated by white rectangles. D) NP protein (green) was co-stained for 




Figure 12. Inclusion-bound SG proteins colocalize with viral RNA species. 
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U2OS cells were infected with EBOV at an MOI of 1, fixed at 24 hours p.i. and analyzed 
by FISH using RNA probes specific for NP positive-sense RNA (A, red) or negative-
sense genomic RNA (B, red). Distribution of the SG protein eIF3 (green) was analyzed 
by IFA. C) U2OS cells were infected and fixed as in (A) but stained for the SG protein 




3.6 HuR does not colocalize with viral RNA. 
 Because the distribution of HuR within viral inclusions was different from that of 
the other SG proteins we examined, we next sought to determine if HuR colocalized with 
viral RNA. U2OS cells were infected with EBOV and examined at 24 hours p.i. by FISH 
using probes binding to viral RNA, and IFA using an antibody against HuR. Although 
HuR was found aggregated in distinct locations in these cells, it did not colocalize with 
either genomic RNA or positive-sense NP RNA (Figure 13).  Instead, HuR was found in 
very close proximity to or surrounding these viral RNA aggregates. These data further 






Figure 13. HuR does not colocalize with viral RNA.  
U2OS cells were infected with EBOV at an MOI of 1 and fixed at 24 hours p.i. Negative-
sense genomic RNA (A, red) or positive-sense NP mRNA (B, red) were examined for 
colocalization with HuR protein (green).  White arrowheads indicate areas of higher 





3.7 Inclusion-bound aggregates are distinct from canonical SGs. 
While many SG proteins aggregated into distinct structures within viral 
inclusions, these structures were larger and less symmetrical in shape than typical SGs 
found in the cytoplasm. As shown in Figure 4, the canonical SG marker protein TIA-1 
was not found as part of the aggregates in inclusions, suggesting that these structures are 
distinct from canonical SGs. Other viruses such as chikungunya virus, Semliki Forest 
virus and vaccinia virus have been shown to induce the formation of granules containing 
various SG components that are morphologically, structurally or functionally different 
from canonical SGs (Panas et al., 2012; Rozelle, Filone, Kedersha, & Connor, 2014; 
Scholte et al., 2015). To more thoroughly distinguish the inclusion bound aggregates 
observed during EBOV infection from canonical SGs, we used cycloheximide (CHX), an 
inhibitor of protein synthesis known to block polysome disassembly and dissolve SGs. 
Canonical SGs disperse upon exposure to CHX, while other virally induced SG-like 
aggregates do not (Kedersha et al., 2000; Rozelle et al., 2014; Scholte et al., 2015). 
EBOV-infected or mock-infected U2OS cells were treated with Ars to induce SG 
formation, and then subsequently treated with CHX. In mock-infected cells treated with 
Ars, SGs completely disassembled upon CHX treatment as expected (Figure 14). When 
EBOV-infected cells were treated with CHX alone, the SG protein aggregates within the 
inclusions, shown by eFI4G (green), persisted and did not disassemble (Figure 14, -Ars, 
+CHX). Ars treatment of EBOV-infected cells led to the formation of SGs in the 
cytoplasm, which dissolved upon CHX treatment. However, despite the dissolution of 
SGs seen within the cytoplasm after CHX treatment, the inclusion bound granules did not 
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disassemble under these conditions (Figure 14, +Ars, + CHX). Thus, while aggregates 
containing certain SG proteins were observed within the viral inclusions during EBOV 
infection, because of their distinct morphology, protein composition and insensitivity to 
CHX treatment, we propose that they represent a unique accumulation of cellular proteins 





Figure 14. Inclusion-bound aggregates are not canonical SGs. 
U2OS cells were infected with EBOV at an MOI of 1.5, incubated for 24 hours and then 
treated with 0.5 mM Ars for 30 minutes (+Ars) or left untreated (-Ars). Cells were 
subsequently treated with either DMSO or 100 µg/ml of CHX for 1 hour and analyzed by 
IFA using antibodies against VP35 (red) and eIF4G antibody (green). Scale bars = 20 






3.8 Preventing SG formation does not impair inclusion-bound aggregate formation. 
To further differentiate these SG like aggregates found in inclusions from 
canonical cytoplasmic SGs we used a doxycycline-inducible U2OS cell line that allows 
overexpression of eGFP-tagged USP10. USP10 is a deubiquitinase that binds to G3BP 
and prevents SG formation by blocking G3BP aggregation (Panas et al., 2015b). When 
left untreated, the U2OS-USP10-eGFP cells did not express USP10-eGFP, and formed 
SGs in the cytoplasm when treated with Ars, as reflected by the punctate distribution of 
HuR which was used as a SG marker (Figure 15A). When these cells were treated with 
doxycycline for 24 hours to induce USP10-eGFP overexpression, SGs formation did not 
occur after Ars treatment, and HuR remained diffusely distributed in cells expressing 
USP10-eGFP.  Overexpression of USP10-eGFP had no effect on EBOV replication and 
allowed for normal inclusion formation in infected cells (Figure 15B). Interestingly, 
although SGs were unable to form in cells overexpressing USP10-eGFP, G3BP was still 
sequestered within viral inclusions (Figure 15C).  This corroborates our findings that the 
aggregates of SG proteins found within viral inclusions during EBOV infection are 
distinct from canonical SGs. Furthermore, SG formation itself is not the impetus for the 





Figure 15. SG formation is not required for sequestration of SG proteins in viral 
inclusions.   
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U2OS-USP10-eGFP cells were treated with doxycycline for 24 hours to induce USP10-
eGFP expression or left untreated. USP10 expression is shown in green by eGFP 
fluorescence. A) Untreated and doxycycline-treated cells were treated with 0.5 mM Ars 
for 30 minutes or left untreated. SGs were visualized using an antibody against HuR 
(red).  B and C) U2OS-USP10-eGFP cells were infected with EBOV at an MOI of 1.5, 
fixed at 24 hours p.i. and analyzed by IFA using an antibody against VP35 (B, red) or 
G3BP (C, red). Infected cells in C were treated with doxycycline for 24 hours prior to 




3.9 Inclusion-bound aggregates do not impair protein translation 
Next we addressed the question of whether inclusion bound granules exert 
antiviral activity in EBOV-infected cells. SG-like granules that are distinct from SGs but 
have antiviral activity have been observed for various viruses, including poxviruses and 
influenza virus (Onomoto et al., 2012; Rozelle et al., 2014; Simpson-Holley et al., 2011). 
Formation of antiviral granules during vaccinia virus infection interferes with protein 
translation, leading to decreased viral titers (Rozelle et al., 2014; Simpson-Holley et al., 
2011). To determine if the inclusion bound granules blocked protein translation during 
EBOV infection, we examined nascent protein synthesis in EBOV-infected cells using 
Click-iT labeling technology. Using this system, newly synthesized proteins were labeled 
in EBOV-infected cells at 24 hours p.i., and viral inclusions and SG marker proteins were 
visualized by co-IFA. While nascent proteins (green) were distributed throughout the 
cytoplasm in mock-infected cells, newly synthesized proteins accumulated in the viral 
inclusions in EBOV-infected cells, despite the presence of SG proteins, suggesting that 
the SG aggregates within inclusions are not detrimental to protein translation (Figure 
16A). Higher magnification images of EBOV infected cells recapitulate that newly 
synthesized proteins are found within viral inclusions and that these inclusions also 
contain sequestered SG proteins (Figure 16B). Transmission electron microscopy (TEM) 
analyses of EBOV-infected Vero cells showed that ribosomes were not present within 
viral inclusions, but were in close proximity (data not shown). Regardless of the size or 
density of viral inclusions, ribosomes were never found interspersed with nucleocapsids 
or viral granular material suggesting that the inclusions are not the sites of viral protein 
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translation. Rather, translation of viral proteins likely occurs in close proximity to 
inclusions with the newly synthesized proteins then transported into viral inclusions. 
Regardless of where viral protein synthesis occurs, the presence of SG proteins within 
viral inclusions did not impair the production or subsequent delivery of newly 
synthesized proteins to viral inclusions during EBOV infection.       





Figure 16. Inclusion-bound aggregates do not interfere with protein translation.  
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A) U2OS cells were mock-infected or infected with EBOV at an MOI of 1.5.  At 24 
hours p.i., cells were pulse-labeled with the amino acid analog L-HPG for 30 minutes.  
Nascent proteins were visualized with an Alex Flour 488 detection reagent specific for L-
HPG, while virus infection was detected with a VP35 antibody (blue) and inclusion-
bound aggregates with an eIF4G antibody (red). Right panels show EBOV-infected cells 
labeled with L-HPG 488 in the absence of VP35 and eIFG4 antibodies. B) Higher 




3.10 EBOV does not block SG formation induced by oxidative stress early during 
infection 
Because the SG-like aggregates found within viral inclusions did not interfere 
with protein translation, we next investigated if their sequestration might play a more pro-
viral role and prevent canonical SG formation in EBOV-infected cells. A number of 
viruses have been shown to not only avoid the induction of the cellular stress response, 
but also actively prevent SG formation during infection (Montero & Trujillo-Alonso, 
2011; J. P. White & Lloyd, 2012). For example, Semliki Forest virus has been shown to 
sequester G3BP aggregates within viral replication centers, which ultimately prevents 
subsequent cytoplasmic SG formation (Panas et al., 2012). Likewise, IAV can suppress 
SG formation not only through PKR antagonism but also via an eIF2α independent 
mechanism mediated by the proteins NP and PA-X (Khaperskyy et al., 2012; 2014). To 
examine if EBOV was able to block SG formation induced by oxidative stress, EBOV-
infected U2OS cells were treated with Ars at different time points p.i. and analyzed by 
IFA using antibodies against VP35 and a panel of SG proteins. SG formation was 
observed in the cytoplasm of EBOV-infected, Ars-treated cells at all time points p.i., as 
shown by staining for eIF4G (Figure 17). Staining for two other canonical SG proteins 
eIF3 and TIA-1 also verified the presence of SGs in EBOV-infected cells after Ars 
treatment (data not shown).  
In contrast to the early time points p.i. when the majority of EBOV-infected, Ars-
treated cells displayed canonical cytoplasmic SGs, at 24 hours p.i. eIF4G was 
homogenously distributed in a significant proportion of infected, Ars-treated cells (Figure 
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18A i). Furthermore, the SGs in many infected and Ars-treated cells appeared more 
diffuse and less punctate compared to Ars-treated, mock-infected cells (Figure 18A ii).  
However, there were infected cells that still possessed canonical SGs within the 
cytoplasm that appeared undisturbed (Figure 18A iii). A quantitative analysis showed that 
while nearly 100% of the mock-infected, Ars-treated cells showed typical punctate 
eIF4G-containing SGs, there was a significant reduction in the number of cells positive 
for canonical SGs in EBOV infected cells at 24 hours p.i. (Figure 18B). Likewise, during 
infection the number of cells deficient in SGs increased by 30% compared to mock-
infected, Ars-treated cells (Figure 18B). The reduction in SGs observed late during 
EBOV infection suggests that although EBOV does not induce SG formation, it might 





Figure 17. EBOV does not prevent Ars-induced SG formation early during 
infection. 
U2OS cells were mock-infected or infected with EBOV at an MOI of 1.5. At the 
indicated time points p.i., cells were treated with 0.5 mM Ars for 30 minutes, fixed and 





Figure 18. SGs are reduced late during infection.  
A) U2OS cells were infected with EBOV at an MOI of 1.5, and treated with 0.5 mM Ars 
at 24 hours p.i. Arrows indicate representative images of the three outcomes of SG 
induction observed, shown at higher magnification on the right. Scale bars = 20 µM. B) 
Quantification of SG-containing cells was performed for three separate experiments. For 
each experiment, 24 fields were randomly chosen and counted. A total number of 290, 
187 and 262 cells were counted, respectively. Counting was performed twice by two 
individual lab members.  Statistical analysis was performed with Graphpad prism 
software, using an unpaired two sample t-test.  
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3.11 EBOV is unable to prevent Ars induced eIF2α phosphorylation 
To dissect the underlying mechanism(s) for the observed reduction in the number 
of SGs in EBOV-infected, Ars-treated cells at 24 hours p.i (Figure 18), we first analyzed 
if EBOV was able to block eIF2α phosphorylation triggered by oxidative stress. We 
performed Western blot analysis to examine the phosphorylation state of eIF2α in 
EBOV-infected cells that were treated with Ars or left untreated at both early and late 
time points p.i. Because high cell density can trigger eIF2α phosphorylation (Savinova & 
Jagus, 1997), we used subconfluent HeLa cells for this experiment. Ars treatment led to 
eIF2α phosphorylation in mock-infected as well as EBOV-infected HeLa cells at all time 
points examined, indicating that although EBOV is able to block PKR signaling and does 
not induce eIF2α phosphorylation (Feng, Cerveny, Yan, & He, 2007b; Olejnik et al., 
2013), it is unable to prevent Ars-induced activation of the signaling pathways leading to 
SG formation (Figure 19). eIF2α was not phosphorylated in EBOV-infected, untreated 
cells at any time examined, which corroborates our results showing that EBOV infection 
per se does not induce eIF2α-triggered SG formation (Figures 3 and 4). Importantly, 
robust eIF2α phosphorylation was observed in EBOV-infected, Ars-treated cells at 24 
hours p.i., indicating that the observed impairment of SG formation cannot be attributed 
to the inhibition of eIF2α phosphorylation induced by oxidative stress.  
To determine if the sequestration of SG proteins within inclusions impaired 
cytoplasmic SG formation and accounted for the reduction in SGs observed late in 
infection, EBOV-infected U2OS cells that were left untreated or treated with Ars at 24 
hours p.i. were closely examined to determine if there was a correlation between the 
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presence of inclusion bound granules and the absence of cytoplasmic SGs. As expected, 
eIF4G was sequestered in a majority of viral inclusions in EBOV-infected, untreated cells 
(Figure 20). Surprisingly, EBOV-infected cells treated with Ars showed little to no 
aggregation of eIF4G within inclusions, and SGs could still form in the cytoplasm of 
most cells. This shows that the sequestration of SG proteins within viral inclusions is not 
sufficient to prevent SG formation induced by cellular stress. It also suggests that 
inclusion-bound SG proteins are not rigidly restrained by viral components and can be 
released into the cytoplasm upon the induction of stress. To understand if this was an Ars 
dependent effect, two other forms of stress were also tested. Similar to Ars, heat-induced 
formation of SGs requires phosphorylation of eIF2α by HRI (Ivanova, Velichko, 
Kantidze, & Razin, 2015; L. Lu, Han, & Chen, 2001).  Hippuristanol however bypasses 
this step and induces SG formation by inhibiting activity of the RNA helicase eIF4A and 
preventing further translation initiation events (Bordeleau et al., 2006; Mazroui et al., 
2006). EBOV-infected U2OS-G3BP-eGFP cells treated with heat or hippuristanol also 
demonstrated cytoplasmic SG formation (data not shown). We therefore propose that the 
sequestration of SG proteins during EBOV infection is not sufficient to prevent SG 





Figure 19. EBOV does not prevent Ars-induced eIF2α phosphorylation.  
HeLa cells were mock-infected or infected with EBOV at an MOI of 1.5 and harvested 
for Western blot analysis at the indicated time points p.i. Prior to cell lysis, cells were 
treated with 0.5 mM Ars for 30 minutes to induce SG formation or left untreated. eIF2α 







Figure 20. SG proteins are not present within inclusions after Ars treatment.  
U2OS cells were infected with EBOV at an MOI of 1.5. At 24 hours p.i., cells were 
mock-treated or treated with 0.5 mM Ars for 30 minutes. Accumulation of SG proteins 
within viral inclusions was visualized by staining for eIF4G (green). Inclusions are 






3.12 Viral inclusions prevent canonical SG formation 
Despite the ability of the inclusion-bound SG proteins to respond to cytoplasmic 
stress, canonical SGs were not present within viral inclusions in EBOV-infected, Ars-
treated cells (Figure 21A). Rather, we observed assorted distributions of SG marker 
proteins and viral inclusions. In a majority of cells, the viral inclusions were completely 
devoid of SG proteins but were surrounded by cytoplasmic SGs (Figure 21A, i). A 
significant number of EBOV-infected cells contained no SGs within either the cytoplasm 
or viral inclusions (Figure 21A, ii). SG-like aggregates were rarely found within large 
viral inclusions (Figure 21A, iii) but were occasionally seen in very small viral inclusions 
(Figure 21B, left panel). Although canonical SGs were predominately absent in large 
inclusions, they were often seen in close proximity to, or surrounded by viral inclusions 
(Figure 21A, middle panel). Late stages of EBOV infection are characterized by large, 
more diffuse inclusions that eventually disperse (Nanbo, Watanabe, Halfmann, & 
Kawaoka, 2013b). In these instances, SGs were often scattered throughout dispersing 
inclusions, but did not colocalize with viral proteins (Figure 21B, right panel). Based on 
these observations we propose that while viral inclusions do not entirely insulate SG 





Figure 21. Stress granules do not form in viral inclusions.   
A) U2OS cells were infected with EBOV at an MOI of 1.5. At 24 hours p.i., the cells 
were treated with 0.5 mM Ars for 30 minutes, fixed and analyzed by IFA. SGs are 
visualized by staining for eIF4G (green) and viral inclusions by VP35 (red). Images are 
representative of what was observed in infected cells. B) U2OS cells were infected as in 
A, but represent a wider array of SG and viral inclusion distributions in infected cells 
Scale bars = 20 µM  
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3.13 VP35 is able to disrupt SG formation 
 Because SG formation was not observed within in viral inclusions (Figure 21), 
we analyzed whether any of the EBOV nucleocapsid proteins were able to interfere with 
the formation of SGs. EBOV NP, VP35, VP30 and VP24 were individually expressed in 
Huh7 cells or U2OS-G3BP-eGFP cells. At 2 days post transfection, the cells were treated 
with Ars or left untreated and examined by IFA for the impact of individual viral proteins 
on SG formation. Of the proteins tested, VP35 was found to disrupt the intracellular 
aggregation of SG proteins under conditions of oxidative stress. To examine if the 
expression level of VP35 correlated with its ability to disrupt SG formation, Huh7 cells 
were transfected with either 0.5 µg or 1.5 µg of a VP35 expression plasmid and analyzed 
at 2 days post transfection. When transfected at a low level (0.5 µg), in untreated cells 
VP35 showed a predominately diffuse distribution in the cytoplasm, with some areas of 
minor clustering (Figure 22A, left panels). This distribution became more aggregated and 
resembled viral inclusions when VP35 was transfected at a much higher level (1.5 µg; 
Figure 22A, right panels). At both low and high levels of VP35 expression, eIF4G 
distribution remained homogenous in the absence of stress. When expressed at lower 
levels, VP35 colocalized with or was in close proximity to SGs in Ars-treated cells. 
While SGs could still form in these cells, they started to appear more diffuse and less 
punctate compared to those in Ars-treated cells lacking VP35 (Figure 22B, VP35 (0.5 
µg); compare cells indicated by white arrow and red arrowhead). SGs were frequently 
surrounded by small, globular VP35 aggregates. At higher expression levels, VP35 was 
found in patch-like structures in the cytoplasm of both untreated and Ars-treated cells 
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(Figure 22A and B) and SG formation was strongly impaired in the Ars-treated cells (Fig 
22B, VP35 (1.5 µg); compare cells indicated by white arrow and red arrowhead). 
Together, these data indicate that VP35 interacts with SGs and is able to disrupt SG 
formation when expressed at sufficiently high levels.  
To determine if VP35 was able to disrupt SG formation induced by other forms of 
stress, we employed two additional methods for inducing SGs.  These include Hipp 
treatment and G3BP overexpression. As described above, Hipp induces SG formation 
independently of eIF2α phosphorylation. Additionally, SGs can be induced through the 
overexpression of certain proteins that are important scaffolds for SG nucleation, 
including TIA-1 and G3BP (Anderson & Kedersha, 2008; Kedersha et al., 2013). When 
Huh7 cells were treated with 1.5 µM Hipp, eIF4G staining showed typical cytoplasmic 
SGs (Figure 23, mock). In Hipp-treated cells transfected with 0.5 µg of a VP35 
expression plasmid, VP35 formed clusters around eIF4G with some areas of 
colocalization as it did after Ars treatment (Figure 23, top panels). SGs were almost 
entirely absent from Hipp-treated cells transfected with 1.5 µg of a VP35 expression 
plasmid (Figure 23, middle panels). To determine if VP35 was also able to disrupt SGs 
induced by the overexpression of G3BP, Huh7 cells were transfected with an expression 
plasmid containing an eGFP-tagged G3BP.  Upon G3BP-eGFP expression in cells, G3BP 
formed large aggregates that were similar to SGs (Figure 24) and contained endogenous 
eIF4G. When these cells were co-transfected with high levels (1.5 µg) of a VP35 
expression plasmid, the G3BP aggregates were reduced in size and became fragmented. 
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Collectively, these data indicate that VP35 is able to disrupt SG formation induced by 
diverse forms of stress. 
VP35 is not diffusely distributed in the cytoplasm of EBOV-infected cells, but is 
directed into the viral inclusions via binding to NP-RNA complexes (Trunschke et al., 
2013). It has been reported previously that the NP to VP35 ratio is crucial for NP-induced 
inclusion formation and that excess expression of VP35 prevents archetypal inclusion 
formation in cells co-expressing NP and VP35 (Noda et al., 2011). To examine if VP35 
was still able to disrupt SG formation in the presence of NP, Huh7 cells were transfected 
with NP and VP35 plasmid DNA in a 1:1 ratio and 2 days after transfection, were treated 
with Ars or left untreated. As expected, VP35 was no longer diffusely distributed in the 
cytoplasm of untreated cells but was directed to NP-induced inclusions (Figure 25A, 
upper left panel; compare to VP35 distribution in Figure 22). Upon Ars treatment, VP35 
remained bound to NP-induced inclusions and did not colocalize with eIF4G-containing 
SGs that formed in the cytoplasm (Figure 25A, upper right panel). When NP 
concentrations were kept low but VP35 was expressed at three fold higher amounts in 
excess of NP, inclusions were dispersed, confirming the previous observations by Noda 
and colleagues (Noda et al., 2011)(Figure 25B, bottom panels). In addition, SG formation 
was significantly reduced under these conditions (Figure 25A and B, bottom panels). This 
might recapitulate the disruption in SG formation seen late in EBOV infection, when 
VP35 expression is high. In summary, our data provide strong evidence that VP35 
interacts with SGs and plays a role in preventing SG formation late in infection when 





Figure 22. VP35 disrupts Ars induced SG formation at high levels of expression.  
Huh7 cells were transfected with low (0.5 µg) or high (1.5 µg) amounts of an HA-VP35 
expression plasmid. At two days post transfection, cells were left untreated (A) or treated 
with 0.5 mM Ars for 30 minutes (B), and fixed. IFA was performed using an HA-specific 
antibody to detect VP35 (red) and an anti- eIF4G antibody (green). White arrows in (B) 
indicate cells expressing VP35, with little to no SG formation. Red arrows indicate cells 
that do not express VP35 and show canonical SG formation.  






Figure 23. VP35 is able to disrupt Hipp induced SG formation.  
Huh7 cells were transfected with increasing amounts of an HA-tagged VP35 expression 
plasmid. At two days post transfection, cells were treated with 1.5 mM Hipp or left 
untreated.  Cells were then fixed and examined by IFA.  VP35 was visualized with an 







Figure 24. VP35 can disrupt G3BP aggregates.  
Huh7 cells were transfected with 0.25 µg of a G3BP-eGFP expression plasmid either in 
the absence or presence of a high concentration (1.5 µg) of an HA-tagged VP35 
expression plasmid or without additional plasmid DNA. VP35 was visualized with an 







Figure 25. VP35 can still disrupt SG formation in the presence of NP. 
Huh7 cells were transfected with expression plasmids expressing EBOV NP or HA-
tagged VP35. Top panels show cells transfected in a 1:1 plasmid ratio of 0.5 µg each per 
well in a 6-well plate. Cells shown in bottom panels were transfected in a NP to VP35 
plasmid ratio of 1:3 (0.5 µg NP DNA, 1.5 µg VP35 DNA).  At two days post transfection, 
cells were treated with 0.5 mM Ars for 30 mins or left untreated, and then imaged by 
IFA. A) Staining was performed using antibodies targeting HA to visualize VP35 (red), 
and eIF4G (green). B) Staining was performed using antibodies targeting NP (red) and 





3.14 Double-stranded RNA binding is not required for VP35’s ability to disrupt SG 
formation 
To further understand the mechanism underlying VP35’s ability to disrupt SG 
formation, we used various VP35 variants (Figure 26) to determine which domains may 
be required for this function. Previous extensive mutational analyses of VP35 have 
shown that residues R305, K309 and R312 within the interferon inhibitory domain (IID) 
are essential for its ability to bind dsRNA, but have no effect on its polymerase cofactor 
functions.  Substitution of either R312 or K309 alone is sufficient to ablate dsRNA 
binding (Bale et al., 2013; Cárdenas et al., 2006; Kimberlin et al., 2010). To determine if 
dsRNA binding is also important for VP35’s capacity to disrupt SG formation, a 
previously described VP35 variant, referred to as VP35-3A, was used. This protein 
possesses the substitutions R305A, K309A, and R312A, which have no effect on NP 
binding or VP35 oligomerization.  However this variant is significantly impaired in its 
ability to block both PKR activation and IFN induction (Schümann et al., 2009). When 
expressed in U2OS cells and examined by IFA, VP35-3A was homogenously distributed 
in the cytoplasm when transfected at a low level (0.5 µg), and more aggregated at a 
higher level (1 µg), similar to the wild type VP35 (Figure 27A). When cells transfected 
with 0.5 µg of VP35-3A plasmid were subsequently treated with Ars, the variant protein 
colocalized with the SG protein eIF4G. In cells transfected with a higher amount (1 µg) 
of VP35-3A plasmid, the variant protein did not colocalize with eIF4G upon Ars 
treatment, and there was a clear reduction in SG formation. When co-expressed in a 1:2 
ratio with NP, VP35-3A colocalized with NP inclusions as expected (Figure 27B). 
  
107 
Furthermore, when NP and VP35-3A expression plasmids were co-transfected at a 1:5 
ratio, NP inclusions began to disperse and resembled those disrupted by wild type VP35. 
The VP35-3A variant therefore behaved identically to the wild type, indicating that 







Figure 26. VP35 wild type and VP35-3A variant schematic.  
A) Schematic of functional domains on wild type VP35. The N-terminus includes 
domains important for oligomerization, NP chaperone function, and 
replication/transcription.  The C-terminus contains the interferon inhibitory domain (IID) 
and includes domains responsible for dsRNA binding and NP binding. B) In the IID 
domain of the VP35-3A variant 3 basic amino acids required for dsRNA binding are 





Figure 27. VP35’s dsRNA binding ability is not required to disrupt SG formation.  
A) U2OS cells were transfected with either 0.5 µg or 1 µg of an HA tagged VP35-3A 
expression plasmid and 2 days post transfection treated with 0.5 mM Ars or left 
untreated.  VP35-3A distribution was visualized using an HA-specific antibody (red). SG 
formation was shown using an eIF4G antibody (green). B) U2OS cells were transfected 
with an expression plasmid encoding EBOV NP (0.5 µg) alone, or in combination with 






















µg or 2.5 µg to a1:2 or 1:5 ratio with NP.  NP (red) and HA-specific (green) antibodies 




3.15 VP35 mediated disruption in SG formation is distinct from NP inclusion disruption 
We next examined if VP35’s ability to disrupt both SGs and NP-induced viral 
inclusions is driven by the same mechanism. Therefore, a VP35 C-terminal deletion 
variant that lacks the last 10 amino acids, here referred to as VP35Δ331-340, was used 
(depicted in Figure 28).  Previous work in the lab has shown that this protein variant has 
negligible NP binding activity and is unable to support polymerase function (unpublished 
data). However, it retains most of its ability to inhibit the IFN response. U2OS cells were 
transfected with increasing concentrations of a VP35Δ331-340 expression plasmid.  
However, VP35Δ331-340 distribution looked nearly identical by IFA regardless of the 
amount of expression plasmid that was transfected.  It is possible that the 10 amino acid 
deletion of this VP35 mutant construct affects its protein expression in these cells. 
Because of the difficulties expressing a range of VP35Δ331-340 expression plasmid 
concentrations, we focused on cells transfected with 1.5 µg of VP35Δ331-340. Two days 
post transfection cells were treated with Ars and examined by IFA. When VP35Δ331-340 
was expressed into U2OS cells it was predominately homogenously distributed 
throughout the cytoplasm (Figure 29A) but did form irregular aggregates in some cells. 
Upon Ars treatment, VP35Δ331-340 was able to disrupt SG formation, although we did 
not observe VP35Δ331-340 colocalizing with or clustering around SGs. As expected, in 
contrast to wild type VP35, VP35Δ331-340 did not colocalize with NP inclusions when 
co-expressed with NP (Figure 29B). Furthermore, NP inclusions remained undisturbed 
with VP35Δ331-340 expression. Although we were unable to more precisely control the 
expression levels of the VP35Δ331-340 variant, these data suggest that the domain 
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required for VP35 to disrupt NP inclusion formation is distinct from the domain required 




Figure 28. Schematic of VP35 deletion variants. 
Cartoon representation of three VP35 deletion variants. These include two N-terminal 
deletion variants, each with a 10 amino acid deletion, labeled VP35Δ22-31 and 
VP35Δ32-41, respectively. Amino acids 20-48 comprise an intrinsically disordered 
region (highlighted in grey). This region is involved in NP binding.  The C-terminal 10 
amino acid deletion in VP35Δ331-340 ablates NP binding, but retains dsRNA binding 







Figure 29. VP35 mediated disruption of SGs is distinct from its disruption of NP 
based inclusions  
A) Huh7 cells were transfected with 1.5 µg of an HA tagged VP35Δ331-340 expression 
plasmid and 2 days post transfection, treated with 0.5 mM Ars or left untreated. 
VP35Δ331-340 distribution was visualized using an HA specific antibody (red) and SG 
formation was shown using an eIF4G antibody (green). B) Huh7 cells were co-
transfected with 0.5 µg of NP expression plasmid and 1.5 µg of VP35Δ331-340 
expression plasmid in a 1:3 ratio.  NP was stained for in red and VP35Δ331-340 was 




3.16 Examination of an intrinsically disordered region on VP35’s function in disrupting 
SG formation 
VP35 has been shown to bind to NP via an intrinsically disordered region (IDR) 
in the N-terminus corresponding to the amino acids 21-48 (Kirchdoerfer et al., 2015; D. 
W. Leung et al., 2015). IDRs are often found in proteins involved in RNA granule 
formation and are thought to be mediators of protein-protein binding and aggregation 
(Kedersha et al., 2013; Molliex et al., 2015). To determine if the IDR of VP35 plays a 
role in the disruption in SG formation observed, we used two VP35 deletion variants that 
possess 10 amino acid deletions in the predicted IDR of VP35. These include deletions of 
amino acids 21-32, and 32-41, respectively. Expression of these VP35 deletion variants 
in untreated U2OS cells revealed a distribution pattern that looked nearly identical to 
wild type VP35 where both showed diffuse cytoplasmic distribution that we assume 
correlated with lower levels of protein expression (Figure 30, white arrows) and more 
aggregated distribution at presumably higher levels of expression (Figure 30, yellow 
arrowheads). Furthermore, upon Ars treatment the VP35 IDR deletion variant could be 
found redistributed into punctate aggregates that surrounded SGs (Figure 31A and B, i). 
When the variants were expressed at higher levels and showed a more aggregated 
distribution in these Ars-treated cells, little to no SG formation was observed (Figure 31A 
and B, ii). These data suggest that partial deletion of the VP35 IDR did not ablate VP35-
mediated SG disruption. However, it is unclear whether removal of the entire IDR had 





Figure 30. Expression of VP35 IDR deletion variants.  
U2OS cells were transfected with 1 µg of expression plasmids encoding HA tagged 
VP35Δ22-31 (top panels) or VP35Δ32-41 (bottom panels). White arrows indicate cells 
with demonstrating diffuse distribution of the indicated VP35 variant protein, while 
yellow arrowheads indicate cells expressing more aggregated distribution of the indicated 







Figure 31. VP35 IDR deletion variants are able to disrupt SG formation.    
U2OS cells were transfected with 1 µg of expression plasmids encoding HA tagged 
VP35Δ22-31 (A) or VP35Δ32-411 (B). Two days post transfections cells were treated 

















with SGs are shown in top panels (i). Cells with disrupted SG formation expressing VP35 
in more aggregated distribution are shown in bottom panels (ii).  Cells were stained for 




EBOV does not induce SG formation during infection and may disrupt SG formation 
independently of eIF2α 
 The increasing number of viruses shown to disrupt or evade SG formation during 
infection has led to the recognition of the cellular stress response as an important antiviral 
mechanism. However, SG formation and the subversion of the cellular stress response 
have never been characterized during EBOV infection. In the work described in this 
chapter, we showed for the first time that EBOV does not induce SG formation at any 
time point p.i. Furthermore, eIF2α was not phosphorylated during the course of infection. 
This is in line with previous studies demonstrating that both eIF2α and PKR are not 
phosphorylated at late stages of EBOV infection (Olejnik et al., 2013; Schümann et al., 
2009). The absence of SG formation observed might at least in part be due to the already 
established function of VP35, to antagonize PKR (Olejnik et al., 2013; Schümann et al., 
2009). Despite the ability of VP35 to block PKR-induced eIF2α phosphorylation, we 
showed that if infected cells were treated with Ars to induce oxidative stress, EBOV was 
unable to prevent phosphorylation of eIF2α or fully block the induction of SGs. This 
suggests that EBOV may only be capable of blocking PKR-mediated SG formation, and 
cannot prevent signaling through the other eIF2α kinases such as HRI.  
 Early in infection a majority of EBOV infected cells formed canonical SGs when 
exposed to oxidative stress. However, SG formation was significantly decreased late in 
infection, despite eIF2α phosphorylation. This indicates that EBOV might have evolved a 
mechanism for disrupting SG formation independently of eIF2α antagonism late during 
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infection. Alternatively, there might be a concentration dependent requirement of VP35 
where early during infection it is able to prevent SG formation induced by viral infection 
itself, but is unable to prevent further SG formation with the addition of supplemental 
stress because cells are limited in the amount of VP35 protein present.  Blocking SG 
formation downstream of eIF2α has been shown for other viruses including poliovirus 
and IAV. In poliovirus-infected cells, the viral 3C protease cleaves G3BP and prevents 
the assembly of SGs late during infection despite eIF2α phosphorylation (J. P. White et 
al., 2007; J. P. White & Lloyd, 2011). Disruption of SG formation by IAV downstream of 
eIF2α phosphorylation is mediated by the viral proteins NP and PA-X (Khaperskyy et al., 
2014). PA-X interferes with PABP, ultimately trapping cellular mRNAs within the 
nucleus. NP was found to disrupt cytoplasmic SG formation when expressed in the 
absence of other viral proteins, and this function was dependent on the oligomerization 
capacity of NP (Khaperskyy et al., 2014). 
 Although it cannot be ruled out that homeostatic cellular processes required for 
proper SG formation are compromised at late stages of infection, we propose that the 
observed impairment of SG formation occurs downstream of eIF2α phosphorylation and 
is mediated by a newly identified function of VP35. When individually expressed in 
cells, VP35 was in close proximity to and clustered around Ars-induced SGs. Higher 
expression levels of VP35 in Ars-treated cells resulted in an almost complete loss of SG 
formation. The same was observed for SGs induced by Hipp and the overexpression of 
G3BP. VP35’s dsRNA binding domain was dispensable for the disruption of SGs, 
suggesting that this function is mediated by a protein-protein interaction and not through 
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an RNA intermediate. It is conceivable that VP35 interacts with an unidentified SG 
component, which then recruits VP35 to SGs upon stress. Subsequently, when VP35 is 
present at high enough levels, it might prevent the oligomerization of its binding partner, 
or inhibit binding of other SG components. A number of host proteins have been shown 
to bind VP35, several of which are found in SGs. VP35 binds to the RNA binding protein 
DRBP76 (also known as NF90), which is involved in PKR activation and SG formation 
during viral infection (Shabman et al., 2011). In a proteomic analysis examining cellular 
proteins associated with filovirus virions, Spurgers et al, found that members of the 
heterogenous nuclear ribonucleoprotein (hnRNP) family, including hnRNP A2.B1, 
hnRNP F and hnRNP AB, bind to VP35 (Spurgers et al., 2010). hnRNP proteins interact 
with other viruses, including poliovirus, dengue virus and Sindbis virus (Brunner, Ertel, 
Rozovics, & Semler, 2010; Ertel, Brunner, & Semler, 2010) (Dechtawewat, 2015) (Gui, 
Lu, Adams, Stollar, & Li, 2010). Importantly, a number of hnRNP proteins as well as 
DRBP76 localize to SGs (Guil, Long, & Cáceres, 2006; Wen et al., 2014) and might act 
as the link between VP35 and SGs.  
 RNA granule formation is promoted by low affinity interactions of RNA binding 
proteins containing IDRs. These regions are characterized by the absence of a defined 
structural motif such as an alpha helix, and low overall hydrophobicity. Many proteins 
important for the nucleation of SGs such as TIA-1 and G3BP contain a number of IDRs 
and areas of low complexity (Calabretta & Richard, 2015; Kedersha et al., 2013). An IDR 
was identified near the amino terminus of VP35 (Kirchdoerfer et al., 2015; D. W. Leung 
et al., 2015) and was shown to mediate binding to NP, maintaining NP in a monomeric 
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state. In line with previous reports, our data show that VP35 is able to disrupt NP-
mediated inclusion formation when expressed in high amounts (Noda et al., 2011). 
Similar to proteins important for SG nucleation, NP serves as a hub for the recruitment of 
other viral proteins including VP35 (Huang et al., 2002; Shi et al., 2008). The disruption 
in inclusion formation by VP35 might be related to its IDR-mediated interaction with NP, 
which impairs NP homo-oligomerization. It is conceivable that through this type of 
interaction, high levels of VP35 interfere with the nucleation of SGs, possibly through 
competitive binding, in a manner similar to its disruption of NP-based inclusion 
formation. Interestingly, two VP35 variants containing non-overlapping 10 amino acid 
deletions spanning parts of the IDR could still impair SG formation. These deletion 
variants however only removed portions of the IDR, suggesting that removal of the full 
length IDR might be necessary to ablate VP35-mediated SG disruption. 
  
SG proteins are sequestered within viral inclusions but are not SG 
 Although SGs were not induced by EBOV infection, numerous SG proteins were 
sequestered within viral inclusions late in infection, but these were not canonical SGs. 
Other viruses including chikungunya, vaccinia virus, Semliki forest virus, and vesicular 
stomatitis virus, have been shown to redistribute SG associated proteins into distinct 
cytoplasmic aggregates with altered protein composition or function compared to 
canonical SGs (Dinh et al., 2013; Fros et al., 2012; Panas et al., 2012; Rozelle et al., 
2014; Simpson-Holley et al., 2011). While the inclusion-bound SG-like aggregates we 
observed during EBOV infection contained many components common to cytoplasmic 
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SGs such as eIF4G, G3BP and eIF3, they were often larger and less symmetrical in shape 
compared to canonical SGs and were devoid of the canonical SG marker protein TIA-1.  
Furthermore, CHX treatment, shown to dissolve canonical SGs, had no effect on the 
aggregation of these proteins within inclusions. CHX-mediated dissolution of SGs is 
driven by the stabilization of polysomes, signifying that SG formation requires a pool of 
messenger ribonucleoprotein (mRNP) complexes independent of ribosomes for their 
formation and persistence (Buchan, Yoon, & Parker, 2011) (Mollet et al., 2008). The 
inclusion-bound aggregates did not dissolve with CHX treatment, indicating that these 
aggregates are composed of translationally silent (viral) mRNAs in complex with 
mRNA-binding proteins. This is in line with both the antiviral granules observed in 
vaccinia virus infection and the proviral G3BP aggregates induced in chikungunya virus 
infection, which were also resistant to dissolution upon CHX treatment (Rozelle et al., 
2014; Scholte et al., 2015; Simpson-Holley et al., 2011). Additionally, the inhibition of 
SG formation mediated through USP10 overexpression had no effect on the aggregation 
of G3BP within inclusions. This suggests that SG formation is not the impetus for 
sequestration within inclusions, and that the inclusion bound aggregates do not represent 
fully formed SGs that are recruited to inclusions, or around which inclusions form. 
 The presence of inclusion-bound aggregates did not impair the accumulation of 
newly synthesized proteins within viral inclusion, indicating that they are not detrimental 
to viral protein translation. This observation, in conjunction with the ability of EBOV to 
grow to high titers despite the presence SG proteins within inclusions indicates that the 
inclusion bound granules are not antiviral and might even be proviral. This is in line with 
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what is known for other viruses including chikungunya virus and West Nile virus, whose 
replication or viral titers were reduced when the SG components G3BP (for chikungunya 
virus) and TIAR (for West Nile virus) were depleted in cells (Emara & Brinton, 2007; W 
Li et al., 2002; Scholte et al., 2015).  
 While EBOV nucleocapsid proteins in viral inclusions did not colocalize with any 
of the SG proteins examined, we showed by FISH analysis that the accumulated SG 
proteins, specifically eIF3, colocalized with both NP positive-sense mRNA and negative-
sense genomic RNA. Interestingly HuR, although found within EBOV inclusions, did not 
colocalize with the other sequestered SG proteins, nor did it colocalize with viral RNA. It 
was instead found in small granules around the viral RNA clusters. It is possible that we 
were unable to detect an interaction between viral RNA and HuR because we only probed 
for NP specific mRNA and genomic RNA, and therefore did not visualize the specific 
target of HuR. Alternatively, HuR might be involved in the regulation of mRNAs on their 
way out of the inclusions to the sites of translation, which we posit does not occur within 
inclusions. TEM analysis showed that ribosomes were not found within viral inclusions, 
indicating that they are not sites of viral protein translation, which most likely occurs in 
close proximity to viral inclusions. Therefore, we speculate that one potential function of 
inclusion-bound SG proteins, many of which are translation initiation factors, may be to 
prepare viral mRNAs for translation. We hypothesize that the difference in aggregation 
and distribution between HuR and the other SG proteins within viral inclusions indicates 
that HuR performs a distinct function compared to the other inclusion bound SG proteins.     
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 The interaction of SG proteins with viral RNAs to promote viral translation or 
replication is not uncommon. G3BP binds to the 3’UTR of the dengue virus genome and 
is speculated to enhance viral translation or RNA replication (B. Jain et al., 2014; Ward et 
al., 2011). Similarly, HuR, which can enhance translation by influencing mRNA stability 
(Barreau et al., 2005; Brennan & Steitz, 2001), binds to the Sindbis virus 3’UTR. 
Depletion of HuR from infected cells resulted in a 10-fold repression in viral growth 
(Sokoloski et al., 2010). Alternatively, binding of SG marker proteins to EBOV RNA 
within the inclusions might prevent dsRNA formation, which we were unable to detect 
despite high levels of both positive and negative-sense RNA within inclusions (data not 
shown).  
Viral inclusions create a proviral environment that prevent canonical SG formation 
 The presence of cellular proteins within viral inclusions might be a common 
proviral mechanism among those viruses that form cytoplasmic inclusion bodies. 
Marburg virus, another member of the filovirus family, recruits the cellular protein 
Tsg101, a component of the endosomal complex required for transport (ESCRT) I, to 
viral inclusions. The interaction of Tsg101 with viral components found within inclusions 
was required for efficient viral budding (Dolnik, Kolesnikova, Stevermann, & Becker, 
2010; Dolnik et al., 2014; Dolnik, Stevermann, Kolesnikova, & Becker, 2015). The 
sequestration of cellular proteins within viral inclusions has also been shown for RSV, 
which recruits HuR into viral inclusions (Lindquist et al., 2010). While the function of 
HuR within RSV inclusions remains inconclusive, RSV inclusions also sequestered the 
antiviral signaling molecules MDA5, RIG-I and MAVS, which resulted in attenuation of 
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the IFN response upon secondary co-infection with Newcastle disease virus (Lifland et 
al., 2012). This supports the hypothesis that the sequestration of certain cellular proteins 
within viral inclusions promotes viral infection by disrupting antiviral signaling 
pathways. Alternatively, the sequestration of proteins involved in cellular antiviral 
signaling pathways in EBOV viral inclusions might prevent the formation of cellular 
granules, similar to SGs, with antiviral function. During infection with an NS1 deficient 
IAV, cytoplasmic SG-like granules, termed antiviral stress granules (avSGs), formed and 
contained both viral RNA and RIG-I, and promoted RIG-I induced IFN production 
(Onomoto et al., 2012). Although it is unclear how NS1 is able to prevent avSG 
formation, its similarities to VP35 suggest that EBOV might also prevent formation of 
similar granules, potentially though sequestration of avSG factors or by an undetermined 
function of VP35.  
 Although we showed that VP35 is able to disrupt SG formation, we also wanted 
to determine whether the reduction in SG formation observed late during infection in the 
presence of additional stress was the result of the sequestration of SG proteins within 
inclusions. Semliki forest virus has been shown to redistribute G3BP into puncta that 
colocalize with viral RNA and prevent SG formation, allowing the virus to avoid SG-
associated translational arrest (McInerney, Kedersha, Kaufman, Anderson, & Liljeström, 
2005; Panas et al., 2012). However, this was not the case for EBOV, as infected cells 
treated with Ars could still form SGs within the cytoplasm, even at one-day post 
infection. Interestingly, EBOV-infected cells treated with Ars no longer showed any 
sequestration of SG proteins within the inclusions. We propose that although the 
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inclusion-bound SG proteins are segregated from the cytoplasmic environment, they are 
not statically associated with inclusions and are able to recycle in and out of this viral 
compartment.  They remain sensitive to stress signals and therefore upon exposure to 
additional stress, might remain in the cytoplasm after egress from inclusions and not 
recycle back into inclusions. The intricacies of SG persistence and disassembly are not 
wholly understood, however it is thought that SGs are highly dynamic structures that 
represent the transient accumulation of RNA and RNA binding proteins. Although they 
can persist for many hours, the proteins that comprise SGs are continuously recycled, 
where any one individual SG protein may not remain statically associated with a single 
SG during the entirety of the stress response (Kedersha et al., 2000; Loschi et al., 2009; 
Nadezhdina, Lomakin, Shpilman, Chudinova, & Ivanov, 2010).  Coupled with the 
dynamic nature of EBOV nucleocapsids (Hoenen et al., 2012b) it is conceivable that the 
inclusion bound aggregates are not rigidly bound by viral inclusions. 
  Even though the sequestered SG proteins still responded to stress signals despite 
being subverted into viral inclusions, SGs did not form within inclusions, suggesting that 
viral inclusions comprise an environment that is resistant to SG formation. We 
hypothesize that this may in part be mediated by the disruption in SG formation observed 
with high expression levels of VP35. Inclusions are rich in VP35 and as such might 
prevent canonical SG formation despite the abundance of many canonical SG 
components. The exclusion of certain canonical SG proteins, such as TIA-1 and the small 
ribosomal subunit, may also preclude canonical SG formation and result in the formation 
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of a distinct species of RNA granule within inclusions. The mechanism of exclusion of 
some SG proteins over others remains to be identified.  
 The dynamic and oscillating nature of stress granules makes them difficult to 
study outside the realm of microscopy{Brielle:2015kh}. As such, the majority of data 
represented in this dissertation make use of various forms of microscopy, focusing 
primarily on fluorescence microscopy. While these techniques allowed for the direct 
visualization of SG formation during EBOV infection, and were critical in the 
identification of SG marker proteins within viral inclusions, it is important to highlight 
that there are both technical and interpretive limitations to these methods. Notably, the 
data obtained are by nature more qualitative rather than quantitative. While a correlation 
can be drawn between the amount of fluorescence in any given image and the amount of 
protein, colocalization or other parameter of interest, it is not a direct measure of such 
parameters. There are a number of factors that confound a quantitative interpretation of 
these data, including cell shape or confluency, antibody affinity or concentration, and 
fluorescence bleed through or photobleaching.  Of relevance to this dissertation are the 
interpretations of the data examining VP35 expression levels and SG formation. The 
limitations to immunofluorescence analysis therefore make it difficult to precisely define 
the amount of VP35 expressed in any individual cell, or the amount of colocalization 
between VP35 and different SG proteins. These limitations however, do not detract from 
the observations made that VP35 disrupts SG formation at high levels of expression and 
we remain confident in the data produced and the conclusions we’ve made from them. 
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 In summary, we have shown for the first time that EBOV does not induce SG 
formation during infection. However, many SG proteins are sequestered within viral 
inclusions, which may be mediated by an interaction between viral RNA and SG-
associated RNA binding proteins. The inclusion-bound aggregates do not represent 
canonical SGs, and do not negatively impact protein translation during infection. 
Furthermore, their sequestration did not prevent the formation of SGs within the 
cytoplasm upon exposure to subsequent stress. However, late during infection SG 
formation was reduced in infected cells exposed to exogenous stress such as Ars and 
Hipp. We have identified a novel function for VP35 by showing that it is able to disrupt 
SG formation and hypothesize that this function is mediated independently of eIF2α 
phosphorylation or the stress-signaling pathway. Finally, we showed that viral inclusions 
are an environment that does not support SG formation, which may in part be due to the 





CHAPTER FOUR: THE ROLE OF POST-TRANSCRIPTIONAL REGULATION 
OF RNA VIA AU-RICH ELEMENTS DURING EBOLA VIRUS INFECTION 
 
Rationale 
A hallmark of EBOV infection is a dysregulated cytokine response that is thought 
to contribute to EBOV pathogenesis and is characterized by the hypersecretion of 
proinflammatory cytokines and chemokines (Ebihara et al., 2011; Villinger et al., 1999; 
Wauquier et al., 2010). However, the mechanisms leading to this dysregulated cytokine 
response are not well understood. Many cytokines and chemokines are regulated at the 
mRNA level by AREs, which serve as important mechanisms for fine-tuning the immune 
response to infection, allowing for immediate and targeted control of gene expression 
(Kafasla et al., 2014; Vlasova-St Louis & Bohjanen, 2014). These AREs are recognized 
by ARE-BPs that impact the stability and localization of mRNAs within the cell and 
thereby influence protein translation. Components of signaling pathways that are 
important for cytokine responses such as NFκB or IFN signaling can also be regulated at 
the mRNA level by AREs to influence cytokine production (Anderson, 2010; Kafasla et 
al., 2014; Palanisamy, Jakymiw, Van Tubergen, D'Silva, & Kirkwood, 2012; Vlasova-St 
Louis & Bohjanen, 2014). Therefore, altered stability of ARE-containing cellular 
mRNAs might contribute to the dysregulated cytokine response observed during EBOV 
infection. Intriguingly, the viral protein VP30 is a ssRNA binding protein that possesses a 
CCCH motif (John et al., 2007; Modrof et al., 2003), which is a hallmark of numerous 
cellular ARE-BPs including TTP and BRF1 (Brooks & Blackshear, 2013; Lai et al., 
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2000; 2002). We therefore sought to determine if VP30 functions as an ARE-BP and 
influences the stability of cellular mRNAs, focusing on two cytokines that are known to 
be dysregulated during EBOV infection, IL-6 and IL-10 (Baize et al., 2002; Bosio et al., 
2003; Ebihara et al., 2011; Panchal et al., 2014; Wauquier et al., 2010). We also 
examined if VP30 has any effect on IKB-α mRNA stability as this molecule is a key 
regulator of NF-κB signaling (Lawrence, 2009).  
The regulation of ARE-containing mRNAs also has implications for viral mRNAs 
but has not been examined for its effects on EBOV replication or pathogenesis. The 
presence of viral mRNAs in the cytoplasm of infected cells leaves them prone to 
recognition by host proteins ARE-BPs, which could negatively impact viral protein 
translation. These cellular proteins could also potentially enhance viral infection by 
stabilizing viral mRNA and increasing viral protein production. As such, many viruses 
interact with ARE-BPs to promote efficient and unimpeded viral infection (Dickson & 
Wilusz, 2011). The EBOV genome is AU-rich (Brauburger et al., 2014; Neumann et al., 
2009) and encodes four viral mRNAs that contain putative AREs within their 3’UTRs. 
These include the mRNAs for the viral proteins NP, VP35, VP30 and VP24. This 
prevalence of AU-rich elements suggests that these EBOV mRNAs might be targets of 
post-transcriptional regulation mediated by ARE-BPs. To explore if EBOV mRNAs can 
be regulated by cellular ARE-BPs, we examined the interaction of two well characterized 
ARE-BPs, TTP and HuR, with EBOV ARE-containing mRNAs. Similarly, we examined 
whether VP30 affects the stability of viral mRNAs as a means of controlling the 




4. 1 Potential role of VP30 as an ARE-BP 
 As mentioned above in chapter one, EBOV VP30 shares a number of features 
with ARE-BPs including the CCCH motif. This domain is conserved among the filoviral 
VP30 proteins and has also been found in the RSV protein M2-1 (Hardy & Wertz, 2000; 
Modrof et al., 2003; Mühlberger, 2007).  A comparison of these zinc finger domains to 
the CCCH motif of TTP is illustrated in Figure 32.  To determine if VP30 is involved in 
ARE-mediated post-transcriptional regulation of mRNA, we tested its function using a 
3’UTR luciferase reporter system. This system involves the use of an expression plasmid 
that contains the firefly luciferase gene under the control of a CMV promoter with a 
multiple cloning site (MCS) downstream of the luciferase gene (Figure 33B). Cis-acting 
regulatory elements can then be inserted into the MCS creating chimeric transcripts. By 
using luciferase activity as a readout and comparing it to the activity of a luciferase 
reporter without any added sequences (Figure 33C), it is possible to examine the effects 
of cis-acting elements on reporter gene activity. We first examined whether VP30 had 
any effect on potential cellular mRNA targets. We focused on three cellular mRNAs that 
play a crucial role in the initiation and regulation of an inflammatory response and might 
play a role in EBOV pathogenesis (Baize et al., 2002; Bosio et al., 2003; Ebihara et al., 
2011; Panchal et al., 2014; Wauquier et al., 2010; Wong, Kobinger, & Qiu, 2014).  These 
include the cytokines IL-6, IL-10 and the regulator of NF-κB signaling, IKB-α. The 
3’UTRs of these genes were cloned into the pMIR-luciferase reporter plasmid and 
transfected into 293T cells, with or without an additional VP30 expression plasmid. In 
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the presence of VP30, there was about a 50% reduction in luciferase activity for the 
3’UTR-luciferase reporter constructs containing the IL-6 and IL-10 3’UTR compared to 
the negative control (Figure 34A). There was no significant difference in luciferase 
activity for the IKB-α 3’UTR reporter construct transfected in the presence of VP30 
compared to the luciferase activity when VP30 was absent. While the 50% decrease in 
luciferase activity for the IL-6 and IL-10 3’UTR reporters was reproducible, the 
reduction was less pronounced than that observed for TTP and its known target IL-6, 
which resulted in 80-90% reduction in luciferase activity. This suggests that the IL-6 and 
IL-10 mRNAs may not be the real targets of VP30-mediated regulation. Instead, the 
overexpression of VP30 might lead to off-target effects leading to nonspecific repression 
in luciferase activity.  
 We also examined if VP30 was able to regulate the stability of any of the four 
viral mRNAs that possess putative AREs in their 3’UTRs. To do so, the 3’UTR luciferase 
reporter constructs containing the 3’UTRs of NP, VP35, VP30 or VP24 were individually 
transfected into 293T cells with or without a VP30 expression plasmid.  Similar to what 
was observed for the cellular 3’UTR targets examined, VP30 mediated a moderate but 
reproducible reduction in luciferase activity for all four viral 3’UTR reporter constructs 
(Figure 34B). However, the ~50% reduction in luciferase reporter activity combined with 
the overexpression of VP30 makes it inconclusive whether these 3’UTRs represent true 





Figure 32. Comparison of CCCH zinc finger domains  
The CCCH zinc finger domain found in EBOV VP30 is conserved among filoviruses and 
can be found in the M2-1 proteins of pneumoviruses such as RSV. These domains are 






Figure 33. Schematic of pMIR-luciferase reporter system and cloning strategy.  
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A) EBOV mRNAs are capped and polyadenylated with varying lengths of 5’ and 
3’UTRs. Four viral transcripts contain putative AREs in their 3’UTRs (example of a 
canonical ARE highlighted in red). B) The luciferase reporter expression system contains 
a firefly luciferase gene with a downstream multiple cloning sight (MCS) followed by a 
polyadenylation signal. The 3’UTRs of cellular genes of interest including IL-6, IL-10 
and IKBα, or four viral genes including NP, VP35, VP30 and VP24, were invidually 
inserted into the pMIR-luciferase reporter expression plasmid downstream of the firefly 
luciferase gene to create chimeric transcripts containing the gene specific 3’UTRs. C) 







Figure 34. VP30 modestly down regulates luciferase reporter activity via 3’UTRs. 
3x10^5 293T cells were seeded per well in 6-well plates and were transfected one day 
later with 200 ng of the indicated 3’UTR-luciferase reporter constructs and 100 ng of B-
gal expression plasmid as a transfection control, with or without an expression plasmid 
encoding VP30 (100 ng). Lysates were harvested two days post transfection and 
luciferase and B-gal activity was measured. Reporter constructs in (A) include the 
3’UTRs of cellular targets IL-6, IL-10 and IKB-α. Reporter constructs in (B) include the 
3’UTRs of viral targets NP, VP35, VP30 and VP24. Luciferase values were normalized 
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to B-gal activity, converted to milliunits.  The normalized luciferase values were then 
compared to those measured in the absence of VP30 for each construct. Data are 
representative of experiments repeated at least 3 times. Statistical analysis was performed 
using GraphPad prism software, using a one-sample t-test. N indicates the number of 
replicates for each condition. * indicates p value ≤ 0.05, ** indicates p value ≤ 0.01, *** 
indicates p value ≤ 0.001. 
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4.2 The 3’UTRs of four EBOV mRNAs contain putative ARES and enhance luciferase 
reporter activity 
Examination of the nucleotide sequences of the seven viral mRNA species made 
during EBOV transcription revealed that four viral nucleocapsid protein mRNAs, NP, 
VP35, VP30 and VP24, contain putative AREs within their 3’UTRs, suggesting they 
might be targets of ARE-BPs. The sequence of each 3’UTR was further examined using 
the online ARE analysis program AREscore (http://arescore.dkfz.de/arescore.pl) to 
confirm that these viral 3’UTRs contain putative AREs. The sequences of each viral 
3’UTR we examined are outlined in Figure 35, with putative AREs highlighted in red. 
These are compared to the 3’UTR of IL-6, a well-characterized target of ARE-mediated 
post-transcriptional regulation, which contains many canonical AREs (Zhao, Liu, & 
Kirkwood, 2008; Zhao, Liu, D'Silva, & Kirkwood, 2011). To first broadly examine 
whether these viral 3’UTRs influence mRNA stability, we employed the pMIR-luciferase 
reporter expression system described above (Figure 33). The 3’UTRs of the respective 
EBOV mRNAs containing putative AREs were inserted into this luciferase reporter 
plasmid downstream of the luciferase open reading frame to create luciferase mRNA 
transcripts containing viral 3’UTRs (Figure 33B). To examine if the EBOV 3’UTRs 
conferred any difference in luciferase reporter activity, 293T cells were transfected with 
luciferase reporter plasmids containing the individual EBOV 3’UTRs along with a B-gal 
reporter plasmid as a transfection control. A reporter plasmid containing no added 3’UTR 
(negative control) and reporter plasmids containing the 3’UTRs of the IL-6 or IKB-α 
mRNA, respectively, were used as controls. Cell lysates were harvested 2 days post 
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transfection and luciferase and B-gal activity was measured (Figure 36).  The luciferase 
reporter activity for each individual 3’UTR-containing reporter plasmid was normalized 
to B-gal and compared to the luciferase values measured for the negative control.  
Interestingly, while the IL-6 and IKB-α 3’UTRs did not have a significant impact on 
luciferase activity compared to the negative control (Figure 36, grey bars), luciferase 
activity was enhanced in cells transfected with the reporter constructs containing the 
EBOV 3’UTRs compared to the negative control (Figure 36, green bars).  This suggests 
that the tested EBOV 3’UTRs might be targeted by cellular proteins involved in 





Figure 35. EBOV 3’UTRs containing putative AREs. 
3’UTR sequences with putative AREs (bolded in red) of four EBOV mRNAs.  The 




Figure 36. Viral 3’UTRs enhance luciferase reporter activity.  
1.5 x10^5 293T cells were seeded per well of a 12-well plate and were transfected one 
day later with 100 ng of luciferase reporter plasmids containing the indicated 3’UTRs and 
100 ng of a B-gal expression plasmid as a transfection control. The luciferase reporter 
containing no added gene specific 3’UTR served as the negative control (Neg. Control). 
Cell lysates were harvested 2 days post transfection and measured for luciferase and B-
gal activity.  Luciferase values were normalized to B-gal activity (converted to 
milliunits), and the normalized luciferase values for the negative control were set to one.  
The normalized luciferase values for each individual 3’UTR-luciferase reporter construct 
were then compared to the negative control.  Statistical analysis was performed using the 
GraphPad Prism software, using a one-sample t-test analysis.   N= 5 for all conditions 
except for the 3’UTR-luciferase reporter containing the IKB-α 3’UTR which was 
repeated only twice. NS indicates p value that is not significant and p> 0.05, * indicates p 
value ≤ 0.05, ** indicates p value ≤ 0.01, *** indicates p value ≤ 0.001.       
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4.3 TTP and BRF1 target the 3’UTR of NP 
We next analyzed if well-characterized ARE-BPs altered the luciferase activity in 
cells co-transfected with the EBOV 3’UTR-containing luciferase reporters plasmids. We 
therefore examined the effects of, TTP, known to destabilize its targets, and HuR, known 
to stabilize its targets, on the 3’UTR-luciferase reporter system (Barreau et al., 2005). 
293T cells were transfected with reporter gene expression plasmids containing the 
individual EBOV 3’UTRs with or without the co-transfection of HuR (Figure 37A) or 
TTP (Figure 37B). The TNF-α 3’UTR was used as a positive control in this experiment 
because the TNF-α mRNA is a known target of HuR and is stabilized by HuR binding 
(Palanisamy et al., 2012). The IL-10 3’UTR is not targeted by HuR and served as an 
additional negative control in this assay. A B-gal expression plasmid was co-transfected 
in all conditions as a transfection control. Lysates were harvested 2 days post transfection 
and luciferase and B-gal activity were measured. The cells co-transfected with EBOV 
3’UTR-luciferase reporter plasmids and the HuR expression plasmid showed little to no 
difference in luciferase reporter activity compared to those not transfected with HuR. 
However, the same level of increase in reporter gene expression was observed with the 
TNF-α 3’UTR positive control. Luciferase activity was only enhanced by about 2-fold in 
cells co-transfected with the reporter plasmid containing the TNF-α 3’UTR and the HuR 
expression plasmid, indicating that the overexpression of HuR did not lead to greatly 
enhanced mRNA stability.  As HuR is constitutively expressed in most cell types (Antic 
& Keene, 1997; Brennan & Steitz, 2001), it is conceivable that the presence of 
endogenous HuR in these transfected cells might account for the small increase in 
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luciferase activity for the TNF-α 3’UTR-containing reporter due to HuR saturation. 
Therefore it is inconclusive whether HuR mediates any effect on the 3’UTRs of EBOV 
mRNAs.     
Interestingly, when the EBOV 3’UTR luciferase reporter plasmids were co-
transfected with TTP, the luciferase activity in cells transfected with the reporter plasmid 
containing the NP 3’UTR was significantly decreased (Figure 37B). This decrease in 
luciferase activity was comparable to what was observed for the luciferase reporters 
containing the 3’UTRs of IL-6 and IL-10, which are both well characterized targets of 
TTP mediated degradation (Brooks & Blackshear, 2013; Palanisamy et al., 2012). The 
cellular protein butyrate response factor 1 (BRF1) is another well studied member of the 
TTP protein family involved in ARE-mediated mRNA degradation (Palanisamy et al., 
2012; Sanduja, Blanco, & Dixon, 2011). Interestingly, cells transfected with the NP 
3’UTR-luciferase reporter plasmid also showed decreased luciferase activity when BRF1 
was co-expressed. However, the BRF-1 experiments are preliminary and need to be 
repeated in order to determine statistical significance. Nevertheless, they suggest that the 
NP mRNA might be the target of multiple cellular ARE-BPs.    
Cells expressing the luciferase reporter plasmids containing the 3’UTRs of VP30 
and VP35 showed an intermediate reduction in luciferase activity in the presence of TTP 
compared to the negative control. Similarly, cells expressing the reporter plasmid 
containing the 3’UTR of VP24 showed little to no change in luciferase activity when TTP 
was co-expressed compared to when it was absent. Together, these data suggest that TTP 




Figure 37.  TTP and BRF1 repress NP 3’UTR-luciferase reporter activity. 
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293T cells were seeded in 12-well plates at a density of 1.5 x 10^5 cells per well and 
transfected one day later with individual luciferase reporter plasmids containing the 
indicated 3’UTR or no gene specific 3’UTR (Neg. Control) along with a B-gal expression 
plasmid as a transfection control.  Cells were transfected with 100 ng of these 3’UTR 
containing luciferase reporter plasmids alone or with an additional expression plasmid 
containing HuR (A, 100 ng), TTP (B, 25 ng), or BRF1 (C, 5-25 ng) respectively. Cell 
lysates were harvested two days post transfection and measured for luciferase and B-gal 
activity. Luciferase values were normalized to B-gal activity, which was converted to 
milliunits.  The normalized luciferase values for the individual 3’UTR-luciferase reporter 
constructs in the presence of the indicated ARE-BP were divided by the normalized 
luciferase values for the individual 3’UTR-luciferase reporter constructs in the absence of 
any ARE-BP. These values were then compared to the negative control, which was set to 
one. N indicates the number of replicates for each condition. Results in (C) were 
collected from an experiment performed once in duplicate.  Statistical analysis was 
performed using the GraphPad Prism software, using their one-sample t-test analysis. NS 
indicates p value that is not significant and p> 0.05,  * indicates p value ≤ 0.05, ** 
indicates p value ≤ 0.01, *** indicates p value ≤ 0.001.    
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4.4 TTP negatively regulates the protein expression and mRNA levels of NP 
To further investigate the downregulation of luciferase reporter activity for the NP 
3’UTR reporter plasmid mediated by TTP, we next examined the effects of TTP on full 
length NP protein expression. To do so, NP expression plasmids containing the open 
reading frame of the NP gene with the full length NP 3’UTR (348 nucleotides), a 
truncated NP 3’ UTR (140 nucleotides) or no 3’ UTR (Figure 38) were transfected into 
293T cells with or without a TTP expression plasmid. Cells were harvested 2 days post 
transfection and examined by Western blot analysis for NP protein expression (Figure 
39). Cells transfected with the NP expression plasmid containing no 3’UTR showed little 
to no reduction in NP protein expression when co-transfected with TTP compared to cells 
transfected without TTP (Figure 39 A and C). However, NP expression was reduced by 
about 75% in cells transfected with the NP expression construct containing the full-length 
3’UTR when TTP was co-expressed. Cells transfected with the NP expression plasmids 
containing either the full length 3’UTR or no 3’UTR showed little to no difference in NP 
protein expression when eGFP was co-expressed instead of TTP. While the protein 
expression of NP was also reduced in cells transfected with the NP expression plasmid 
containing a truncated 3’UTR in the presence of TTP (Figure 39 B and C), this reduction 
was not as pronounced as what was observed when cells were co-transfected with TTP 
and the NP expression plasmid containing a full length 3’UTR.  
To determine if the reduction in NP protein expression was recapitulated at the 
mRNA level, mRNA was collected from cells transfected with the NP expression 
plasmid containing a full length 3’UTR, with or without co-transfection of TTP, at one 
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day post transfection. NP mRNA levels were quantified by qRT-PCR using primers that 
bind to sequences within the ORF of NP mRNA.  When TTP was co-expressed with the 
NP expression plasmid containing the full length 3’UTR, NP mRNA levels were 
dramatically reduced compared to cells transfected with the NP expression plasmid 
containing the full length 3’UTR in the absence of TTP.  This was recapitulated when 
cells were transfected with the TTP and the pMIR-luciferase 3’UTR reporter expression 
plasmid containing the NP 3’UTR and luciferase mRNA levels were measured by qRT-
PCR. Collectively, these data suggest that TTP specifically targets the 3’UTR of NP 
mRNA, which ultimately leads to a reduction in NP protein expression. Shortening of the 
3’UTR mitigates the reduction in NP protein expression observed in the presence of TTP, 
suggesting that the NP 3’UTR contains multiple AREs or other cis-acting elements that 





Figure 38. Schematic of NP expression plasmids with varying lengths of 3’UTR  
Schematic representation of the mRNA transcripts produced from the expression 
plasmids containing the full length NP gene with varying 3’UTR lengths. The full length 
NP 3’UTR is 348 nucleotides (nt) and the truncated 3’UTR is 140 nt in length. The 
partial 3’UTR contains the 140 nt directly following the NP ORF. The last construct 





Figure 39. TTP negatively impacts NP protein expression.  
A) 3x10^ 5 293T cells were seeded into 6-well plates and transfected one day later with 
200 ng expression plasmids containing the NP gene with either a full length 3’UTR, or no 
3’UTR.  These plasmids were transfected in the absence or presence of 25 ng of a TTP 
expression plasmid. As a control, NP expression plasmids were co-transfected with 25 ng 
of an eGFP expression plasmid instead of TTP. Cells were harvested two days post 
transfection and analyzed by Western blot.  This blot is representative of three 
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independent experiments. Tubulin was used as a control for endogenous cellular protein 
amount.  B) Cells were transfected as in (A) but with an NP expression plasmid 
containing a truncated 3’UTR in the presence or absence of 25 ng of a TTP expression 
plasmid. Lamin B was used as a control for endogenous cellular protein amount. This 
blot is representative of three independent experiments. C) Quantification of NP protein 
expression in the presence of TTP using NP expression plasmids containing no 3’UTR, a 
partial 3’UTR, or a full length 3’UTR. Protein bands were quantified using Li-COR 
Image Studio western blot analysis software. Statistical analysis was performed using 
GraphPad prism software, using a one-sample t-test. ** indicates p value ≤ 0.01, *** 
indicates p value ≤ 0.001.      





Figure 40. NP mRNA levels are reduced in the presence of TTP   
3x10^5 293T cells were seeded in 6-well plates and one day later were transfected with 
200 ng of the expression plasmids containing the full length NP 3’UTR downstream of 
either the full length NP gene or the firefly luciferase gene, with or without the co-
transfection of 25 ng of a TTP expression plasmid. 100 ng of eGFP plasmid were also 
transfected as a transfection control. Cellular RNA was harvested one day post 
transfection using an RNA isolation method that isolates mRNA and miRNA. NP mRNA 
levels (left columns) or luciferase mRNA levels (right columns) were measured by qRT-
PCR using 5 ng RNA and primers specific for either NP or luciferase. The levels of 
mRNA were calculated using the ΔΔCT method with Bio-Rad CFX Manager 1.5 software 
and were normalized to beta-2-microglobulin. Levels of mRNA measured in the absence 




4.5 TTP overexpression impairs minigenome activity. 
In order to determine if the targeting effects of TTP on NP had any impact on 
viral replication or transcription, the EBOV minigenome system was used.  This system, 
is described above in chapter three (Figure 9).  293T cells were transfected with a 
plasmid containing the 3E5E-eGFP minigenome under the control of the T7 RNA 
polymerase promoter, along with an expression plasmid encoding the T7 RNA 
polymerase. In addition, plasmids encoding the EBOV genes NP, VP30, VP35 and L, all 
under the control of the T7 RNA polymerase promoter, were transfected. All of these 
support plasmids contain full length 3’UTRs. As expected, when cells were examined 
two days post-transfection, there was no eGFP expression in the absence of L (Figure 
41A). In the presence of L, eGFP was expressed, indicative of proper replication and 
transcription.  When TTP was co-expressed with the minigenome and support plasmids, 
eGFP expression was significantly reduced. There was also a decrease in eGFP 
expression when cells were co-transfected with mCherry instead of TTP, indicating that 
the expression of an additional protein might contribute to the reduction in minigenome 
activity observed when TTP was co-expressed. However, because the reduction in eGFP 
expression was much greater in the presence of TTP than mCherry, we propose that the 
inhibitory effects observed when TTP was overexpressed can be mainly attributed to TTP 
activity.  
To quantify the decrease in minigenome activity in cells overexpressing TTP, an 
EBOV minigenome containing firefly luciferase as the reporter gene was used. Using 
luciferase activity as the readout of minigenome activity corroborated what was shown 
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with the eGFP minigenome. Luciferase activity was significantly reduced when TTP was 
co-expressed (Figure 41B). Co-transfection of a mCherry again lead to a reduction in 
minigenome activity, but this inhibitory effect was still less than that observed for TTP.  
Combined, our data suggest that TTP inhibits EBOV replication by downregulating NP 





Figure 41. TTP overexpression decreases minigenome activity. 
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A) 3 x10 ^5 293T cells were seeded in a 6-well plate and transfected one day later with 
the 3E-5E-eGFP minigenome and appropriate support plasmids all driven by a T7 RNA 
polymerase promoter. Cells were co-transfected with the expression plasmids for the L 
polymerase, TTP (50 ng), or mCherry (50 ng) as indicated. Cells were live imaged 2 days 
post transfection.  Experiment was performed twice. B) Cells were transfected as in (A) 
but with the 3E-5E-luciferase minigenome instead of the 3E-5E-eGFP minigenome. Cells 
were co-transfected with the B-gal reporter plasmid as a transfection control.  Lysates 
were harvested 2 days post transfection and luciferase and B-gal values were measured.  
Luciferase activity was normalized to B-gal activity, converted to milliunits. The 
normalized luciferase values for cells transfected with the minigenome in the absence of 
TTP were set to one and compared to the normalized luciferase values for cells co-
transfected with the minigenome and TTP. Data presented are the luciferase values 






VP30 has similarities to TTP 
Because of its similarities to other proteins involved in post-transcriptional 
regulation of mRNA, we examined whether the viral protein VP30 was able to function 
in a manner similar to other ARE-BPs such as HuR and TTP. VP30 expression 
consistently and reproducibly led to a moderate decrease of about 50% in luciferase 
activity from constructs with an ARE-containing 3’UTR. However, VP30 did not appear 
to specifically target one of the tested cellular or viral UTRs. The slight decrease in 
reporter gene expression might be due to high VP30 expression levels in the transfected 
cells. When TTP was expressed at high levels, it was found to exhibit a moderate off-
target repressive effect on luciferase activity. This repression was similar to the level of 
repression observed for VP30.  Although it is inconclusive whether VP30 specifically 
targets any of the 3’UTRs constructs we tested, the observed reduction in luciferase 
activity, albeit only about 2 fold, suggests that VP30 may in fact function similarly to 
TTP.   
Viral 3’UTRs influence protein expression 
 Viruses interact with the host RNA regulation machinery in a number of different 
ways (Charley & Wilusz, 2014; Dickson & Wilusz, 2011). This often entails the 
avoidance or disruption of the cellular mechanisms that impair viral infection such as 
RNA interference, innate immune signaling and RNA degradation. Alternatively, many 
viruses have been shown to exploit these pathways to their own advantage. The EBOV 
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genome is enriched in A and U residues and as such represents a potential target for 
specific cellular RNA binding proteins influencing mRNA turnover via AREs. We 
identified four viral mRNAs containing putative AREs within their 3’UTRs and aimed to 
determine if these regions are targeted by the RNA regulating machinery, either for 
stabilization or degradation of the viral mRNAs. When expressed in cells, reporter 
plasmids containing the viral 3’UTRs showed enhanced luciferase activity compared to 
the luciferase reporter construct containing no additional 3’UTR. This suggests that the 
viral 3’UTRs enhanced the stability or promoted the translation of the luciferase gene. 
The interaction between ARE-BPs and viral RNA is not uncommon. HuR, which is 
associated with mRNA stability and enhanced translation, has been shown to interact 
with a number of viruses, and was found sequestered within viral inclusions in EBOV-
infected cells. We therefore hypothesized that it might be targeting viral mRNA and 
ultimately enhancing the translation of viral proteins. However, HuR only induced a 
modest increase in luciferase activity when co-expressed with luciferase reporter 
plasmids containing the viral 3’UTRs. This was also the case for a reporter construct 
containing the TNF-α 3’UTR, a known target of HuR (Barreau et al., 2005; Brennan & 
Steitz, 2001). It is important to note that HuR is ubiquitously expressed, and most cell 
lines express HuR efficiently (Brennan & Steitz, 2001).  Therefore it is possible that the 
cells we used for transfection were already saturated with HuR and overexpression of 
HuR would not lead to enhanced mRNA stability and subsequent increased luciferase 
reporter activity. Efforts to knockdown HuR in 293T and HeLa cells using an siRNA 
approach failed. This might be due to the function of HuR as an important regulator of 
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the cell cycle. Furthermore, it has not been possible to breed HuR knockout mice, 
supporting the notion that it is difficult to establish a cell system in which HuR 
expression is abolished or limited (Brennan & Steitz, 2001; Simone & Keene, 2013).  
Despite these challenges, the localization of HuR within viral inclusions as shown in 
chapter three suggests that HuR plays a role during viral infection, and we aim to study 
this in more detail in the future.     
 
TTP negatively targets the NP 3’UTR 
TTP and BRF1 are known to destabilize their RNA targets, often through the 
recruitment of RNA processing and decay enzymes such as deadenylases and exosome 
components (Brooks & Blackshear, 2013; Carrick & Blackshear, 2007; Lai et al., 2000). 
Our data suggest that TTP and BRF1 target the 3 ‘UTR of the EBOV NP mRNA. The 
luciferase reporter activity for the NP 3’UTR construct co-transfected with TTP was 
comparable to that observed for the luciferase constructs containing the 3’UTRs of IL-6 
and IL-10, two known targets of TTP (Brooks & Blackshear, 2013).  This was 
recapitulated at the RNA level, when luciferase mRNA levels were measured by qRT-
PCR. The luciferase activity of the 3’UTR reporter plasmids encoding the three other 
viral 3’UTRs showed less than a 50% reduction in the presence of TTP.  Previous 
experiments aiming to optimize the luciferase reporter system showed that transfection of 
higher TTP plasmid amounts led to the unspecific downregulation of luciferase activity 
from constructs that did not possess an ARE-containing 3’UTR (data not shown).  
However, TTP transfected at lower concentrations still showed a potent negative 
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regulatory effect on specific targets, while making little difference to the negative control. 
This suggests that the slight reduction in luciferase reporter activity for the 3’UTR 
reporter constructs containing the VP30 and VP35 3’UTRs might be due to a nonspecific 
or off-target effect of TTP.  It is also conceivable that TTP binds to the putative AREs 
within these 3’UTRs with low affinity, leading to a mild effect.  
 We further showed that TTP was able to down-regulate full-length NP protein 
expression.  This negative effect was ablated when the 3’UTR of NP was removed, 
indicating that TTP recognizes specific elements within the NP 3’UTR. Furthermore, 
TTP was able to down regulate minigenome activity. However, it is unclear if this effect 
was due to TTP’s downregulation of NP protein expression or was mediated by another 
potential target such as the genomic RNA itself. While we hypothesize that TTP directly 
targets the NP 3’UTR and promotes NP mRNA degradation, it is also conceivable that 
TTP mediates this effect in a more indirect way. ARE-BPs often share the same or 
overlapping targets and thereby can create a gradient of regulatory control based on the 
abundance of certain ARE-BPs over others (Barreau et al., 2005; Kafasla et al., 2014). 
TTP might compete for binding to other cellular RNA targets, thereby freeing up an 
unknown ARE-BP that is then able to bind to the NP 3’UTR. It is also feasible that the 
increase in TTP expression in this system might be indirectly affecting luciferase activity 
via an off-target effect.  TTP might down regulate the expression of a stability factor that 
recognizes the NP 3’UTR, which would then promote the turnover of the NP mRNA.  
Future studies will be aimed at more precisely defining the mechanism of TTP-mediated 
downregulation of NP protein expression and minigenome activity.   
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We hypothesized in chapter three that viral inclusions promote viral replication 
through the recruitment of cellular factors that are beneficial to this process.  TTP did not 
colocalize with viral RNA species within viral inclusions (Figure 12), which supports the 
hypothesis that inclusions are important proviral environments. However, TTP 
expression is not nearly as ubiquitous as that of HuR (Carrick & Blackshear, 2007), 
making it possible that the cell lines we used were not ideal for examining TTP 
localization during infection.  As a key regulator of inflammatory responses, TTP is 
upregulated in immune cells such as monocytes and macrophages upon activation 
(Brooks & Blackshear, 2013). These are also thought to be primary target cells of EBOV 
infection (Feldmann & Geisbert, 2011b; Messaoudi et al., 2015). Therefore it would be 
interesting to examine whether TTP can be found associated with inclusions or RNA in 
cells that express higher or more physiological levels of TTP such as macrophages.    
While the sequestration of certain cellular proteins might promote EBOV 
replication or translation, the exclusion of other cellular proteins, such as TTP, might 
provide an equally important function for EBOV. TIA-1, which was also excluded from 
EBOV inclusions, is a critical component of SGs but is also an ARE-BP that has been 
shown to target viral RNA and promote mRNA degradation (Albornoz, Carletti, Corazza, 
& Marcello, 2014). Although it is unclear how certain cellular proteins are sequestered 
within inclusions while others are excluded, because many ARE-BPs have overlapping 
targets, it is possible that the sequestration of HuR, or another related protein, allows 
HuR to outcompete or prevent TTP or TIA-1 from binding viral RNA. 
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 In summary, we have shown that the 3’UTR of NP is subject to regulation by at 
least one cellular protein involved in the control of mRNA stability. This protein, TTP, 
was able to downregulate the protein expression of NP only when it possessed at least a 
partial 3’UTR.  TTP also significantly impaired EBOV minigenome activity, although it 
is unclear whether this function was mediated solely through its targeting of NP. While 
HuR was not found to mediate any substantial effect on viral 3’UTRs, its sequestration 
within viral inclusions fosters the notion that HuR plays some undetermined role during 
EBOV infection. Finally, we have shown that VP30 possesses characteristics common to 
ARE-BPs like TTP. We were unable to find a specific RNA target, but propose that a real 






CHAPTER FIVE: CONCLUDING REMARKS 
Overview 
The ongoing outbreak of Ebola virus disease in West Africa has had significant 
and widespread global health consequences, highlighting the importance of 
understanding its highly pathogenic causative agent. Since its discovery, considerable 
research efforts have focused on understanding the interaction between EBOV and the 
host immune response. These studies have shown that EBOV causes significant immune 
dysfunction and possesses a number of immune evasion strategies, which contribute to its 
relatively uninhibited viral spread. One aspect of this aberrant immune response is the 
uncontrolled release of proinflammatory cytokines and chemokines, leading to a cytokine 
storm that has been associated with fatal infection(Baize et al., 2002; Bird et al., 2015; 
Ebihara et al., 2011; Mohamadzadeh et al., 2006; Wauquier et al., 2010). Furthermore, 
the evasion of innate antiviral immunity is typified by the disruption in type I IFN 
production and signaling(Audet & Kobinger, 2015; Basler, 2015). Other immune evasion 
mechanisms include the antagonism of various sensors of viral infection including RIG-I 
(Cárdenas et al., 2006) and PKR (Feng, Cerveny, Yan, & He, 2007a; Schümann et al., 
2009). The extent to which EBOV is able to disrupt, evade or inhibit a robust antiviral 
response is not wholly understood, and this emphasizes the importance of more precisely 
defining these mechanisms. Identifying cellular factors that the virus interacts with or 
antiviral pathways that the virus is unable to evade is valuable for the development of 
effective antiviral strategies.      
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Two cellular processes predominantly involved in maintaining homeostasis are 
increasingly becoming appreciated as mediators of innate antiviral responses. These 
include the translational repression associated with SG formation during the cellular 
stress response and the post-transcriptional regulation of mRNA via AREs and their 
associated RBPs(Dickson & Wilusz, 2011; Onomoto et al., 2014). However, there have 
been no studies examining the effects of SG formation or post-transcriptional regulation 
of viral RNA during EBOV infection. Here we examined these two cellular systems in 
more depth in the context of EBOV infection.  
 
Summary of Major Findings 
In Chapter Three we explored the interaction between EBOV and the cellular 
stress response.  The key findings we made are:  
• SGs were not induced at any time point during the course of EBOV infection. 
This is supported by the absence of eIF2α phosphorylation both early and late 
in infection.  
• Despite the observed absence of SGs, EBOV was unable to fully prevent SG 
formation induced by other stresses including Ars, heat, or Hipp treatment. 
• SG proteins were found sequestered within viral inclusions late in infection, 
and colocalized with both positive sense mRNA and negative sense genomic 
RNA within inclusions. These inclusion bound granules were not canonical 
SGs, however, and did not impair protein translation during infection.   
• Canonical SGs did not form within inclusions. 
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• When additional stress was applied to EBOV infected cells late in infection, 
SG proteins were no longer found sequestered within inclusions. Furthermore, 
there was a reduction in cytoplasmic SG formation compared to early stages 
of infection.  
• A newly identified function of the viral IFN antagonist VP35 was discovered. 
VP35 disrupted SG formation when expressed at high levels. Mutational 
analysis revealed that this function was independent of VP35’s IFN inhibitory 
domain.     
 
In Chapter Four we examined if the 3’UTRs of viral mRNAs containing putative 
AREs are targets of post-transcriptional regulation. Furthermore, we tested if VP30 
functions as an ARE-BP and targets these specific viral 3’UTRs or the 3’UTRs of 
selected cellular mRNAs with links to the dysregulated cytokine response observed 
during infection. The key findings are: 
• In cells expressing VP30, the luciferase activity of the reporter gene constructs 
containing the IL-6 or IL-10 3’UTR was modestly decreased, while the luciferase 
activity of the IKB-α 3’UTR reporter construct was not affected. Coexpression of 
VP30 with the reporter constructs containing the EBOV 3’UTRs led to a 2-fold 
reduction in luciferase activity. A similar modest decrease in reporter gene 
activity was also observed when TTP was overexpressed at higher levels along 
with non-specific target 3’UTRs, making it is conceivable that VP30 has an 
mRNA destabilizing activity, but the true targets remain to be identified 
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• Using online bioinformatics tools, it was predicted that the 3’UTRs of four EBOV 
mRNAs, NP, VP35, VP30 and VP24, contain AREs. 
• Cells transfected with luciferase reporter plasmids containing the 3’UTRs of the 
four EBOV genes showed increased luciferase activity compared to the luciferase 
reporter without any gene specific 3’UTR, suggesting that the viral UTRs enhance 
protein expression.  
• Overexpression of HuR, a stabilizing ARE-BP that was found in EBOV 
inclusions, led to slightly enhanced luciferase activity for the reporter constructs 
containing the investigated EBOV 3’UTRs. However, endogenous HuR leading 
to potential saturation effects makes it inconclusive whether the viral 3’UTRs are 
real targets of HuR.  
• Overexpression of TTP and BRF1, both destabilizing ARE-BPs, led to a 
significant decrease in luciferase reporter activity for the 3’UTR-luciferase 
reporter construct containing the NP 3’UTR. In addition, NP mRNA amounts and 
protein expression levels were reduced in cells overexpressing TTP. This effect 
was dependent on the presence of the NP 3’UTR. Overexpression of TTP also led 
to decreased EBOV minigenome activity. Combined, these results suggest that the 
NP 3’UTR is a target for TTP and BRF1. 
•  
Overarching Implications and Significance 
This body of work focused on characterizing the dynamics between EBOV and 
two specific yet interconnected mechanisms of cellular RNA regulation implicated in 
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host antiviral responses.  While much work remains to be done in order to more precisely 
characterize these events, this work demonstrates for the first time that EBOV is 
intimately involved in these processes. By gaining a better understanding of the 
intracellular events that take place during EBOV infection, we continue to improve and 
design more appropriate treatments and vaccines.        
  While we show that EBOV does not induce the stress response during infection, 
we also show that it was unable to fully prevent the induction of SGs mediated by 
exogenous stress. This provides insight into potential weaknesses of EBOV and suggests 
the possibility of therapeutic intervention.  By inducing translational arrest via stress 
response pathways that EBOV is unable to block or disrupt, it would be possible to shut 
down EBOV translation and obstruct viral replication. Similar work was done for IAV, 
which has also been shown to prevent SG formation during the entirety of infection.  
Although IAV could prevent PKR mediated SG formation, it was remained sensitive to 
strong inducers of SG formation early during infection. When the drug Pateamine A was 
used to induce SG formation and translational arrest early during infection, viral RNA 
and protein levels were significantly reduced (Khaperskyy et al., 2014). While treating a 
systemic infection with therapeutics designed to induce SGs and shutdown protein 
translation seems risky, a number of promising chemotherapeutic agents have been 
shown to induce SGs with minimal toxicity suggesting that it may be possible (Anderson, 
Kedersha, & Ivanov, 2015). Furthermore, the widely used anti-inflammatory drug 
indomethacin induces PKR activation independently of dsRNA or IFN and was shown to 
inhibit VSV protein translation and replication without harming the cells (Amici et al., 
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2015). Therefore, drugs like Pateamine A and indomethacin might prove beneficial as 
prophylactic or therapeutic intervention against EBOV infection.    
A common thread between the two chapters of this dissertation is the interaction 
between EBOV and the RNA regulatory proteins TTP and HuR. We show that HuR was 
found sequestered within viral inclusions but showed a distinct aggregation pattern 
compared to the other SG proteins identified. Similarly, while many of the inclusion-
bound aggregate proteins colocalized with viral RNA, HuR was instead found in clusters 
surrounding, or in very close proximity to viral RNA. TTP on the other hand, which we 
show was able to target and negative regulate the expression of EBOV NP, was excluded 
from viral inclusions. These data suggest that viral inclusions recruit host factors that are 
beneficial for viral replication and provide a protective environment for viral RNA. 
Furthermore, it is conceivable that cellular proteins that negatively impact viral 
replication are excluded from viral inclusions. Understanding the mechanisms underlying 
the specific recruitment of certain host factors over others may also help in the 
development of therapeutics that target viral inclusions, whose proper function is critical 
for viral replication and pathogenesis.           
 
Future Directions 
  Our studies identified three critical observations of cellular events that take place 
during EBOV infection that open the door to important future studies. First, we showed 
that SG formation did not occur during infection, but that EBOV was unable to fully 
prevent the induction of SG formation when exogenous stress was applied. Therefore, it 
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would be interesting to characterize the effects of stress-induced translational repression 
on EBOV replication using drugs such as Ars or Hipp, which do not signal through PKR. 
Furthermore, the precise mechanism of VP35-mediated PKR antagonism, a function we 
propose is primarily responsible for the absence of SGs during infection, remains unclear. 
Therefore, future studies should focus on determining the precise mechanism of PKR 
inhibition. This would provide a potential point for chemotherapeutic or small molecule 
intervention.  
 The second important point brought up by this research is the interaction between 
a diverse panel of cellular SG proteins and EBOV components within viral inclusions. 
We showed that many SG proteins including eIF4G, eIF3 and PABP were sequestered 
within viral inclusions and colocalized with viral RNA species. These proteins did not 
seem to have a negative effect on viral protein translation. However future studies should 
be done to determine 1) how these proteins are getting into and are aggregating within 
viral inclusions and 2) if they serve to enhance viral replication. Live cell imaging studies 
might provide more insight into the dynamics and assembly of these inclusion bound 
aggregates. It would be interesting to determine more definitively if these aggregates are 
static complexes, or much like SGs themselves, are more fluid and involve the 
continuous recycling or shuttling of individual components. Furthermore, it would be 
valuable to identify if one or many of these proteins functions in a proviral capacity, 
perhaps by stabilizing viral RNA, or sequestering signaling molecules away from 
cytoplasmic signaling networks.  Similarly, it would be interesting to examine whether all 
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infected cell types show sequestered proteins within viral inclusions, or if there are 
potential differences that may better inform us as to the function of these proteins.    
Finally, we were able to show that EBOV mRNAs, and potentially genomic 
RNA, are prone to recognition by RNA regulatory proteins such as TTP. TTP is an 
important regulatory protein primarily in immune cells such macrophages and dendritic 
cells (Bros et al., 2010; Carrick & Blackshear, 2007). While we observed that TTP was 
able to target and negatively regulate the expression of NP and significantly decreased 
minigenome activity, it is unclear if this effect influences the outcome of viral replication.  
It would be interesting to determine if EBOV shows enhanced replication in cells 
deficient in TTP, or conversely if EBOV replication is restricted in cells with high levels 
of TTP. Although we were unable to determine if HuR was also able to target viral 
RNAs, we propose that its localization within viral inclusions is highly suggestive of a 
potential role during EBOV infection. Ablating HuR expression in cells is difficult due to 
the important role of HuR in cell survival. However, human HuR knockout cell lines 
were recently established using CRISP-Cas9 technology.  These cell lines could be used 
as tools to determine if the expression of viral mRNAs is altered in the absence of HuR or 
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